Michael R. Hayden - Publications

Affiliations: 
University of British Columbia, Vancouver, Vancouver, BC, Canada 
Area:
Biostatistics Biology

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Harding RJ, Xie Y, Caron NS, Findlay-Black H, Lyu C, Potluri N, Chandrasekaran R, Hayden MR, Leavitt BR, Langbehn DR, Southwell AL. Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification. Biorxiv : the Preprint Server For Biology. PMID 39386513 DOI: 10.1101/2024.09.25.614766  0.657
2024 Sogorb-Gonzalez M, Landles C, Caron NS, Stam A, Osborne G, Hayden MR, Howland D, van Deventer S, Bates GP, Vallès A, Evers M. Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington disease models. Brain : a Journal of Neurology. PMID 39155061 DOI: 10.1093/brain/awae266  0.347
2024 Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Staffler G, Hayden MR, et al. Corrigendum to "Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease" [Neurobiology of Disease, 2024 Jan:190:106376]. Neurobiology of Disease. 106444. PMID 38402018 DOI: 10.1016/j.nbd.2024.106444  0.673
2024 Caron NS, Aly AE, Black HF, Martin DDO, Schmidt ME, Ko S, Anderson C, Harvey EM, Casal LL, Anderson LM, Rahavi SMR, Reid GSD, Oda MN, Stanimirovic D, Abulrob A, ... ... Hayden MR, et al. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 38215984 DOI: 10.1016/j.jconrel.2024.01.011  0.304
2023 Bartl S, Xie Y, Potluri N, Kesineni R, Hencak K, Cengio LD, Balazs K, Oueslati A, Parth M, Salhat N, Siddu A, Smrzka O, Cicchetti F, Straffler G, Hayden MR, et al. Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease. Neurobiology of Disease. 106376. PMID 38092268 DOI: 10.1016/j.nbd.2023.106376  0.693
2023 Duarte F, Vachey G, Caron NS, Sipion M, Rey M, Perrier AL, Hayden MR, Déglon N. Limitations of dual-sgRNA CRISPR strategies for the treatment of CNS genetic disorders. Human Gene Therapy. PMID 37658843 DOI: 10.1089/hum.2023.109  0.325
2023 Van Raamsdonk JM, Al-Shekaili HH, Wagner L, Bredy TW, Chan L, Pearson J, Schwab C, Murphy Z, Devon RS, Lu G, Kobor MS, Hayden MR, Leavitt BR. Huntingtin Decreases Susceptibility to a Spontaneous Seizure Disorder in FVN/B Mice. Aging and Disease. PMID 37199581 DOI: 10.14336/AD.2023.0423  0.671
2023 Joachimiak P, Ciesiołka A, Kozłowska E, Świtoński PM, Figura G, Ciołak A, Adamek G, Surdyka M, Kalinowska-Pośka Ż, Figiel M, Caron NS, Hayden MR, Fiszer A. Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models. Bmc Biology. 21: 17. PMID 36726088 DOI: 10.1186/s12915-023-01515-3  0.308
2022 Chan LL, Hill A, Lu G, Van Raamsdonk J, Gascoyne R, Hayden MR, Leavitt BR. Huntingtin Overexpression Does Not Alter Overall Survival in Murine Cancer Models. Journal of Huntington's Disease. PMID 36442204 DOI: 10.3233/JHD-220554  0.639
2022 Caron NS, Banos R, Aly AE, Xie Y, Ko S, Potluri N, Anderson C, Black HF, Anderson LM, Gordon B, Southwell AL, Hayden MR. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice. Neurobiology of Disease. 166: 105652. PMID 35143966 DOI: 10.1016/j.nbd.2022.105652  0.705
2021 Bhattacharyya A, Trotta CR, Narasimhan J, Wiedinger KJ, Li W, Effenberger KA, Woll MG, Jani MB, Risher N, Yeh S, Cheng Y, Sydorenko N, Moon YC, Karp GM, Weetall M, ... ... Hayden M, et al. Small molecule splicing modifiers with systemic HTT-lowering activity. Nature Communications. 12: 7299. PMID 34911927 DOI: 10.1038/s41467-021-27157-z  0.683
2021 Lemarié FL, Caron NS, Sanders SS, Schmidt ME, Nguyen YTN, Ko S, Xu X, Pouladi MA, Martin DDO, Hayden MR. Rescue of aberrant huntingtin palmitoylation ameliorates mutant huntingtin-induced toxicity. Neurobiology of Disease. 105479. PMID 34390831 DOI: 10.1016/j.nbd.2021.105479  0.664
2021 Ravalia AS, Lau J, Barron J, Purchase S, Southwell AL, Hayden MR, Nafar F, Parsons MP. Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice. Neurobiology of Disease. 105293. PMID 33556538 DOI: 10.1016/j.nbd.2021.105293  0.688
2020 Caron NS, Banos R, Yanick C, Aly AE, Byrne LM, Smith ED, Xie Y, Smith SEP, Potluri N, Findlay Black H, Casal L, Ko S, Cheung D, Kim H, Seong IS, ... ... Hayden MR, et al. Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33310753 DOI: 10.1523/JNEUROSCI.1865-20.2020  0.696
2020 Machiela E, Jeloka R, Caron NS, Mehta S, Schmidt ME, Baddeley HJE, Tom CM, Polturi N, Xie Y, Mattis VB, Hayden MR, Southwell AL. The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons. Frontiers in Aging Neuroscience. 12: 524369. PMID 33192449 DOI: 10.3389/Fnagi.2020.524369  0.805
2020 Xu X, Ng B, Sim B, Radulescu CI, Yusof NABM, Goh WI, Lin S, Lim JSY, Cha Y, Kusko R, Kay C, Ratovitski T, Ross C, Hayden MR, Wright G, et al. pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model. Cell Death & Disease. 11: 809. PMID 32978366 DOI: 10.1038/s41419-020-02983-z  0.801
2020 Wright GEB, Caron NS, Ng B, Casal L, Casazza W, Xu X, Ooi J, Pouladi MA, Mostafavi S, Ross CJD, Hayden MR. Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease. Human Molecular Genetics. PMID 32898862 DOI: 10.1093/Hmg/Ddaa184  0.641
2020 Findlay Black H, Wright GEB, Collins JA, Caron N, Kay C, Xia Q, Arning L, Bijlsma EK, Squitieri F, Nguyen HP, Hayden MR. Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32741964 DOI: 10.1038/S41436-020-0917-Z  0.371
2020 Squitieri F, Mazza T, Maffi S, De Luca A, AlSalmi Q, AlHarasi S, Collins JA, Kay C, Baine-Savanhu F, Landwhermeyer BG, Sabatini U, Hayden MR. Tracing the mutated HTT and haplotype of the African ancestor who spread Huntington disease into the Middle East. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32661355 DOI: 10.1038/S41436-020-0895-1  0.375
2020 Skotte NH, Pouladi MA, Ehrnhoefer DE, Huynh K, Qiu X, Nielsen SMB, Nielsen TT, Nørremølle A, Hayden MR. Compromised IGF signaling causes caspase-6 activation in Huntington disease. Experimental Neurology. 113396. PMID 32622701 DOI: 10.1016/J.Expneurol.2020.113396  0.644
2020 Bartl S, Oueslati A, Southwell AL, Siddu A, Parth M, David LS, Maxan A, Salhat N, Burkert M, Mairhofer A, Pankevych H, Balazs K, Staffler G, Hayden MR, Cicchetti F, et al. Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. Neurobiology of Disease. 104943. PMID 32407769 DOI: 10.1016/J.Nbd.2020.104943  0.684
2019 Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, Anderson LM, Ko S, Zhu X, van Deventer SJ, Evers MM, Konstantinova P, Hayden MR. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Research. PMID 31745548 DOI: 10.1093/Nar/Gkz976  0.716
2019 Kay C, Collins JA, Caron NS, Agostinho LA, Findlay-Black H, Casal L, Sumathipala D, Dissanayake VHW, Cornejo-Olivas M, Baine F, Krause A, Greenberg JL, Paiva CLA, Squitieri F, Hayden MR. A Comprehensive Haplotype Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. American Journal of Human Genetics. PMID 31708117 DOI: 10.1016/J.Ajhg.2019.10.011  0.355
2019 Ehrnhoefer DE, Skotte NH, Reinshagen J, Qiu X, Windshügel B, Jaishankar P, Ladha S, Petina O, Khankischpur M, Nguyen YTN, Caron NS, Razeto A, Meyer Zu Rheda M, Deng Y, Huynh KT, ... ... Hayden MR, et al. Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. Cell Chemical Biology. PMID 31353319 DOI: 10.1016/J.Chembiol.2019.07.001  0.329
2019 Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA. Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience. 13: 209. PMID 31156395 DOI: 10.3389/Fncel.2019.00209  0.365
2019 Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiology of Disease. PMID 31108174 DOI: 10.1016/J.Nbd.2019.05.009  0.376
2019 Wright GEB, Collins JA, Kay C, McDonald C, Dolzhenko E, Xia Q, Bečanović K, Drögemöller BI, Semaka A, Nguyen CM, Trost B, Richards F, Bijlsma EK, Squitieri F, Ross CJD, ... ... Hayden MR, et al. Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. American Journal of Human Genetics. PMID 31104771 DOI: 10.1016/J.Ajhg.2019.04.007  0.772
2019 Ferrari Bardile C, Garcia-Miralles M, Caron NS, Rayan NA, Langley SR, Harmston N, Rondelli AM, Teo RTY, Waltl S, Anderson LM, Bae HG, Jung S, Williams A, Prabhakar S, Petretto E, ... Hayden MR, et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 31015293 DOI: 10.1073/Pnas.1818042116  0.652
2019 Kang R, Wang L, Sanders SS, Zuo K, Hayden MR, Raymond LA. Altered Regulation of Striatal Neuronal -Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model. Frontiers in Synaptic Neuroscience. 11: 3. PMID 30846936 DOI: 10.3389/Fnsyn.2019.00003  0.373
2019 Ionescu A, Gradus T, Altman T, Maimon R, Saraf Avraham N, Geva M, Hayden M, Perlson E. Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1 Model. Cell Death & Disease. 10: 210. PMID 30824685 DOI: 10.1038/S41419-019-1451-2  0.355
2019 Francardo V, Geva M, Bez F, Denis Q, Steiner L, Hayden MR, Cenci MA. Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 30756361 DOI: 10.1007/S13311-018-00699-9  0.339
2018 Ryskamp D, Wu L, Wu J, Kim D, Rammes G, Geva M, Hayden M, Bezprozvanny I. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. Neurobiology of Disease. PMID 30594810 DOI: 10.1016/J.Nbd.2018.12.022  0.348
2018 Martin DDO, Schmidt ME, Nguyen YT, Lazic N, Hayden MR. Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201701510RRR. PMID 30423259 DOI: 10.1096/Fj.201701510Rrr  0.367
2018 Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. Molecular Neurobiology. PMID 30334188 DOI: 10.1007/S12035-018-1393-1  0.815
2018 Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, ... ... Hayden MR, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Science Translational Medicine. 10. PMID 30282695 DOI: 10.1126/Scitranslmed.Aar3959  0.72
2018 Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature Reviews. Drug Discovery. PMID 30237454 DOI: 10.1038/Nrd.2018.133  0.375
2018 Schmidt ME, Buren C, Mackay JP, Cheung D, Dal Cengio L, Raymond LA, Hayden MR. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. Bmc Biology. 16: 58. PMID 29945611 DOI: 10.1186/S12915-018-0526-3  0.393
2018 Martin DDO, Kay C, Collins JA, Nguyen YT, Slama RA, Hayden MR. A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease. Scientific Reports. 8: 8096. PMID 29802276 DOI: 10.1038/S41598-018-25903-W  0.422
2018 Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Molecular Neurodegeneration. 13: 25. PMID 29783994 DOI: 10.1186/S13024-018-0259-3  0.66
2018 Petrella LI, Castelhano JM, Ribeiro M, Sereno JV, Gonçalves SI, Laço MN, Hayden MR, Rego AC, Castelo-Branco M. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. Human Molecular Genetics. PMID 29668904 DOI: 10.1093/Hmg/Ddy119  0.404
2018 Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR. Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathologica Communications. 6: 16. PMID 29510748 DOI: 10.1186/S40478-018-0518-0  0.716
2018 Chevre R, Trigueros-Motos L, Castaño D, Chua T, Corlianò M, Patankar JV, Sng L, Sim L, Juin TL, Carissimo G, Ng LFP, Yi CNJ, Eliathamby CC, Groen AK, Hayden MR, et al. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201701084RR. PMID 29481310 DOI: 10.1096/Fj.201701084Rr  0.303
2018 Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, ... ... Hayden MR, et al. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. PMID 29460498 DOI: 10.1002/Ajmg.B.32618  0.734
2018 Bardile CF, Garcia-Miralles M, Caron N, Langley S, Teo RTY, Petretto E, Hayden MR, Pouladi MA. A43 Intrinsic mutant HTT-mediated defects in oligodendroglia cells contribute to myelin deficits and behavioural abnormalities in huntington disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.41  0.811
2018 Bartl S, Oueslati A, Southwell AL, Parth M, Salhat N, Siddu A, Burkert M, Pankevych H, David L, Villanueva EB, Xie Y, Cengio LD, Ko S, Hayden MR, Cicchetti F, et al. I09 Antibodies inhibit cell to cell transmission of mutant HTT Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.245  0.68
2018 Klein P, Karneva Z, Toonen L, Kim H, Caron N, Graaf Lvd, Buil L, Horst Gvd, Anthonijsz H, Ham Fvd, Beumer W, Hayden M, Song J, Roon-Mom Wv, Platenburg G. I01 QRX-704, a novel antisense oligonucleotide therapy, designed to prevent hd pathology while maintaining htt function Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.237  0.408
2017 Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. Jci Insight. 2. PMID 29212949 DOI: 10.1172/Jci.Insight.95665  0.652
2017 Ehrnhoefer DE, Southwell AL, Sivasubramanian M, Qiu X, Villanueva EB, Xie Y, Waltl S, Anderson L, Fazeli A, Casal L, Felczak B, Tsang M, Hayden MR. HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. Human Molecular Genetics. PMID 29121340 DOI: 10.1093/Hmg/Ddx394  0.725
2017 Kay C, Hayden MR, Leavitt BR. Epidemiology of Huntington disease. Handbook of Clinical Neurology. 144: 31-46. PMID 28947124 DOI: 10.1016/B978-0-12-801893-4.00003-1  0.413
2017 Silva AC, Ferreira IL, Hayden MR, Ferreiro E, Cristina Rego A. Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease. Biochimica Et Biophysica Acta. PMID 28939435 DOI: 10.1016/J.Bbadis.2017.09.009  0.378
2017 Ellrichmann G, Blusch A, Fatoba O, Brunner J, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R. Laquinimod treatment in the R6/2 mouse model. Scientific Reports. 7: 4947. PMID 28694434 DOI: 10.1038/S41598-017-04990-1  0.379
2017 Martin DDO, Hayden MR. Neurodegeneration: Role of repeats in protein clearance. Nature. PMID 28445458 DOI: 10.1038/Nature22489  0.339
2017 Naia L, Cunha-Oliveira T, Rodrigues J, Rosenstock TR, Oliveira A, Ribeiro M, Carmo C, Oliveira-Sousa SI, Duarte AI, Hayden MR, Rego AC. Histone deacetylase inhibitors protect against pyruvate dehydrogenase dysfunction in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28123081 DOI: 10.1523/Jneurosci.2006-14.2016  0.38
2017 Southwell AL, Skotte NH, Villanueva EB, Østergaard ME, Gu X, Kordasiewicz HB, Kay C, Cheung D, Xie Y, Waltl S, Dal Cengio L, Findlay-Black H, Doty CN, Petoukhov E, Iworima D, ... ... Hayden MR, et al. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics. PMID 28104789 DOI: 10.1093/Hmg/Ddx021  0.803
2017 Hayden MR, Kay C. Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 88: 334-335. PMID 28093515 DOI: 10.1212/Wnl.0000000000003528  0.342
2016 Kay C, Tirado-Hurtado I, Cornejo-Olivas M, Collins JA, Wright G, Inca-Martinez M, Veliz-Otani D, Ketelaar ME, Slama RA, Ross CJ, Mazzetti P, Hayden MR. The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. European Journal of Human Genetics : Ejhg. PMID 28000697 DOI: 10.1038/Ejhg.2016.169  0.353
2016 Sanders SS, Parsons MP, Mui KK, Southwell AL, Franciosi S, Cheung D, Waltl S, Raymond LA, Hayden MR. Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. Bmc Biology. 14: 108. PMID 27927242 DOI: 10.1186/S12915-016-0333-7  0.684
2016 Skotte NH, Sanders SS, Singaraja RR, Ehrnhoefer DE, Vaid K, Qiu X, Kannan S, Verma C, Hayden MR. Palmitoylation of caspase-6 by HIP14 regulates its activation. Cell Death and Differentiation. PMID 27911442 DOI: 10.1038/Cdd.2016.139  0.379
2016 Ryskamp D, Wu J, Geva M, Kusko R, Grossman I, Hayden M, Bezprozvanny I. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiology of Disease. PMID 27818324 DOI: 10.1016/J.Nbd.2016.10.006  0.373
2016 Jan A, Jansonius B, Delaidelli A, Somasekharan SP, Bhanshali F, Vandal M, Negri GL, Moerman D, MacKenzie I, Calon F, Hayden MR, Taubert S, Sorensen PH. eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathologica. PMID 27752775 DOI: 10.1007/S00401-016-1634-1  0.306
2016 Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, ... ... Hayden MR, et al. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America. PMID 27671624 DOI: 10.1073/Pnas.1607843113  0.366
2016 Naia L, Rosenstock TR, Oliveira AM, Oliveira-Sousa SI, Caldeira GL, Carmo C, Laço MN, Hayden MR, Oliveira CR, Rego AC. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models. Molecular Neurobiology. PMID 27590140 DOI: 10.1007/S12035-016-0048-3  0.359
2016 Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Scientific Reports. 6: 31652. PMID 27528441 DOI: 10.1136/Jnnp-2016-314597.263  0.653
2016 Geva M, Kusko R, Soares H, Fowler K, Birnberg T, Barash S, Merenlender Wagner A, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, ... ... Hayden MR, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Human Molecular Genetics. PMID 27466197 DOI: 10.1093/Hmg/Ddw238  0.374
2016 Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, Xie Y, Anderson L, Felczak B, Waltl S, Ko S, Cheung D, Dal Cengio L, Slama R, Petoukhov E, ... ... Hayden MR, et al. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Human Molecular Genetics. PMID 27378694 DOI: 10.1093/Hmg/Ddw212  0.737
2016 Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, Davidson M, Slama RA, Hayden MR. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. PMID 27335115 DOI: 10.1212/Wnl.0000000000002858  0.327
2016 Ehrnhoefer DE, Caron NS, Deng Y, Qiu X, Tsang M, Hayden MR. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Experimental Neurology. PMID 27296315 DOI: 10.1016/J.Expneurol.2016.06.008  0.364
2016 Masellis M, Collinson S, Freeman N, Tampakeras M, Levy J, Tchelet A, Eyal E, Berkovich E, Eliaz RE, Abler V, Grossman I, Fitzer-Attas C, Tiwari A, Hayden MR, Kennedy JL, et al. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. Brain : a Journal of Neurology. PMID 27190009 DOI: 10.1093/Brain/Aww109  0.357
2016 Maillet A, Tan K, Chai X, Sadananda SN, Mehta A, Ooi J, Hayden MR, Pouladi MA, Ghosh S, Shim W, Brunham LR. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Scientific Reports. 6: 25333. PMID 27142468 DOI: 10.1038/Srep25333  0.612
2016 Teo RT, Hong X, Yu-Taeger L, Huang Y, Tan LJ, Xie Y, To XV, Guo L, Rajendran R, Novati A, Calaminus C, Riess O, Hayden MR, Nguyen HP, Chuang KH, et al. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Human Molecular Genetics. PMID 27126634 DOI: 10.1093/Hmg/Ddw122  0.653
2016 Connolly C, Magnusson-Lind A, Lu G, Wagner PK, Southwell AL, Hayden MR, Björkqvist M, Leavitt BR. Enhanced Immune Response to MMP3 stimulation in Microglia Expressing Mutant Huntingtin. Neuroscience. PMID 27033979 DOI: 10.1016/J.Neuroscience.2016.03.031  0.711
2016 Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P. Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. Molecular Therapy. Nucleic Acids. 5: e297. PMID 27003755 DOI: 10.1038/Mtna.2016.7  0.69
2016 Wijesekara N, Kaur A, Westwell-Roper C, Nackiewicz D, Soukhatcheva G, Hayden MR, Verchere CB. ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice. Diabetologia. PMID 26970755 DOI: 10.1007/S00125-016-3907-6  0.3
2016 Riechers SP, Butland S, Deng Y, Skotte N, Ehrnhoefer DE, Russ J, Laine J, Laroche M, Pouladi MA, Wanker EE, Hayden MR, Graham RK. Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. Human Molecular Genetics. PMID 26908611 DOI: 10.1093/Hmg/Ddw036  0.771
2016 Naia L, Ribeiro M, Rodrigues J, Duarte AI, Lopes C, Rosenstock TR, Hayden MR, Rego AC. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides. PMID 26876526 DOI: 10.1016/J.Npep.2016.01.009  0.331
2016 Garcia-Miralles M, Ooi J, Bardile CF, Tan LJ, George M, Drum CL, Lin RY, Hayden MR, Pouladi MA. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Experimental Neurology. PMID 26825854 DOI: 10.1016/J.Expneurol.2016.01.019  0.803
2016 Dobson L, Träger U, Farmer R, Hayardeny L, Loupe P, Hayden MR, Tabrizi SJ. Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. Journal of Neurochemistry. PMID 26823290 DOI: 10.1111/Jnc.13553  0.305
2016 Graham RK, Laroche M, Lessard-Beaudoin M, Garcia-Miralles M, Kreidy C, Yu-Tager L, Hayden MR, Nguyen HP, Pouladi MA. B42 Early olfactory behaviour deficits associated with olfactory bulb atrophy and caspase-8 activation in HD rodent models Journal of Neurology, Neurosurgery & Psychiatry. 87: A24.1-A24. DOI: 10.1136/Jnnp-2016-314597.73  0.764
2016 Miralles MG, Tan LJ, Lim M, Geva M, Hayden MR, Pouladi MA. L6 Evaluation of pridopidine in the transgenic yac128 mouse model of huntington’s disease Journal of Neurology, Neurosurgery & Psychiatry. 87: A92.1-A92. DOI: 10.1136/Jnnp-2016-314597.261  0.635
2016 Miniarikova J, Zanella I, Blits B, Evers M, Zimmer V, Spoerl A, Southwell A, Hayden M, Deventer Sv, Deglon N, Petry H, Konstantinova P. L5 Pre-clinical evaluation of aav5-mihtt gene therapy of huntington’s disease in rodents Journal of Neurology, Neurosurgery & Psychiatry. 87: A91.3-A92. DOI: 10.1136/Jnnp-2016-314597.260  0.702
2016 Kay C, Collins J, Miedzybrodzka Z, Wright G, Madore S, Gordon E, Gerry N, Fisher E, Davidson M, Slama R, Hayden M. I2 Huntington’s disease reduced penetrance alleles occur at high frequency and affect age-related increases in prevalence Journal of Neurology, Neurosurgery & Psychiatry. 87: A59.3-A60. DOI: 10.1136/Jnnp-2016-314597.167  0.339
2015 Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Huntington disease. Nature Reviews. Disease Primers. 1: 15005. PMID 27188817 DOI: 10.1038/nrdp.2015.5  0.306
2015 Sanders SS, Martin DD, Butland SL, Lavallée-Adam M, Calzolari D, Kay C, Yates JR, Hayden MR. Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers. Plos Computational Biology. 11: e1004405. PMID 26275289 DOI: 10.1371/Journal.Pcbi.1004405  0.346
2015 Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26201449 DOI: 10.1038/Mt.2015.128  0.701
2015 Southwell AL, Smith SE, Davis TR, Caron NS, Villanueva EB, Xie Y, Collins JA, Li Ye M, Sturrock A, Leavitt BR, Schrum AG, Hayden MR. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific Reports. 5: 12166. PMID 26174131 DOI: 10.1038/Srep12166  0.693
2015 Hitchcock E, Patankar JV, Tyson C, Hrynchak M, Hayden MR, Gibson WT. A novel microdeletion affecting the CETP gene raises HDL-associated cholesterol levels. Clinical Genetics. PMID 26126777 DOI: 10.1111/Cge.12633  0.306
2015 Jan A, Karasinska JM, Kang MH, de Haan W, Ruddle P, Kaur A, Connolly C, Leavitt BR, Sorensen PH, Hayden MR. Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression. Neuroscience Letters. 598: 66-72. PMID 25957561 DOI: 10.1016/J.Neulet.2015.05.007  0.311
2015 Bečanović K, Nørremølle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G, Manoharan S, Doty CN, Beck J, Lahiri N, Portales-Casamar E, Warby SC, Connolly C, ... ... Hayden MR, et al. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease. Nature Neuroscience. 18: 807-16. PMID 25938884 DOI: 10.1038/Nn.4014  0.373
2015 Stroedicke M, Bounab Y, Strempel N, Klockmeier K, Yigit S, Friedrich RP, Chaurasia G, Li S, Hesse F, Riechers SP, Russ J, Nicoletti C, Boeddrich A, Wiglenda T, Haenig C, ... ... Hayden MR, et al. Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Research. 25: 701-13. PMID 25908449 DOI: 10.1101/Gr.182444.114  0.667
2015 Sanders SS, Hayden MR. Aberrant palmitoylation in Huntington disease. Biochemical Society Transactions. 43: 205-10. PMID 25849918 DOI: 10.1042/Bst20140242  0.436
2015 Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Human Molecular Genetics. 24: 3257-71. PMID 25740845 DOI: 10.1093/Hmg/Ddv080  0.706
2015 Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Dar Santos R, Coleman AJ, Carter K, Creighton S, Bechtel N, Bohlen S, Reilmann R, Johnson HJ, Hayden MR, Tabrizi SJ, et al. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 393-401. PMID 25690257 DOI: 10.1002/Mds.26118  0.347
2015 Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, ... ... Hayden MR, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 76: 46-56. PMID 25662335 DOI: 10.1016/J.Nbd.2015.01.002  0.796
2015 Østergaard ME, Thomas G, Koller E, Southwell AL, Hayden MR, Seth PP. Biophysical and biological characterization of hairpin and molecular beacon RNase H active antisense oligonucleotides. Acs Chemical Biology. 10: 1227-33. PMID 25654188 DOI: 10.1021/Cb500880F  0.648
2015 Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, Offen D. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Human Molecular Genetics. 24: 2604-14. PMID 25616965 DOI: 10.1093/Hmg/Ddv023  0.352
2015 Brunham LR, Hayden MR. Human genetics of HDL: Insight into particle metabolism and function. Progress in Lipid Research. 58: 14-25. PMID 25601427 DOI: 10.1016/J.Plipres.2015.01.001  0.301
2015 Wong BK, Ehrnhoefer DE, Graham RK, Martin DD, Ladha S, Uribe V, Stanek LM, Franciosi S, Qiu X, Deng Y, Kovalik V, Zhang W, Pouladi MA, Shihabuddin LS, Hayden MR. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiology of Disease. 76: 24-36. PMID 25583186 DOI: 10.1016/J.Nbd.2014.12.030  0.807
2015 Sanders SS, Hou J, Sutton LM, Garside VC, Mui KK, Singaraja RR, Hayden MR, Hoodless PA. Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. Developmental Biology. 397: 257-66. PMID 25478910 DOI: 10.1016/J.Ydbio.2014.11.018  0.415
2015 Semaka A, Kay C, Belfroid RD, Bijlsma EK, Losekoot M, van Langen IM, van Maarle MC, Oosterloo M, Hayden MR, van Belzen MJ. A new mutation for Huntington disease following maternal transmission of an intermediate allele. European Journal of Medical Genetics. 58: 28-30. PMID 25464109 DOI: 10.1016/J.Ejmg.2014.11.005  0.762
2015 Ooi J, Hayden MR, Pouladi MA. Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. Molecular Neurobiology. 52: 1850-61. PMID 25398695 DOI: 10.1007/S12035-014-8974-4  0.637
2015 Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR. Autophagy in Huntington disease and huntingtin in autophagy. Trends in Neurosciences. 38: 26-35. PMID 25282404 DOI: 10.1016/J.Tins.2014.09.003  0.375
2015 Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry Molecular Therapy. DOI: 10.1038/mt.2015.128  0.664
2015 Southwell AL, Skotte NH, Caron N, Kordasiewicz H, Oestergaard M, Doty CN, Villanueva EB, Xie Y, Felczak B, Freier SM, Swayze EE, Seth PP, Frank Bennet C, Hayden MR. 696. Pre-Clinical Evaluation of Allele-Specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides Molecular Therapy. 23: S277. DOI: 10.1016/S1525-0016(16)34305-2  0.728
2014 Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, ... Hayden MR, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. Plos One. 9: e107434. PMID 25207939 DOI: 10.1371/Journal.Pone.0107434  0.826
2014 Southwell AL, Skotte NH, Kordasiewicz HB, Østergaard ME, Watt AT, Carroll JB, Doty CN, Villanueva EB, Petoukhov E, Vaid K, Xie Y, Freier SM, Swayze EE, Seth PP, Bennett CF, ... Hayden MR, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2093-106. PMID 25101598 DOI: 10.1038/Mt.2014.153  0.822
2014 Rinninger F, Heine M, Singaraja R, Hayden M, Brundert M, Ramakrishnan R, Heeren J. High density lipoprotein metabolism in low density lipoprotein receptor-deficient mice. Journal of Lipid Research. 55: 1914-24. PMID 24954421 DOI: 10.1194/Jlr.M048819  0.319
2014 Singaraja RR, Tietjen I, Hovingh GK, Franchini PL, Radomski C, Wong K, vanHeek M, Stylianou IM, Lin L, Wang L, Mitnaul L, Hubbard B, Winther M, Mattice M, Legendre A, ... ... Hayden MR, et al. Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. Journal of Lipid Research. 55: 1693-1701. PMID 24891332 DOI: 10.1194/Jlr.M048710  0.337
2014 Kolodziejczyk K, Parsons MP, Southwell AL, Hayden MR, Raymond LA. Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease. Plos One. 9: e94562. PMID 24728353 DOI: 10.1371/Journal.Pone.0094562  0.718
2014 Butland SL, Sanders SS, Schmidt ME, Riechers SP, Lin DT, Martin DD, Vaid K, Graham RK, Singaraja RR, Wanker EE, Conibear E, Hayden MR. The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease. Human Molecular Genetics. 23: 4142-60. PMID 24705354 DOI: 10.1093/Hmg/Ddu137  0.68
2014 Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clinical Genetics. 86: 29-36. PMID 24646433 DOI: 10.1111/Cge.12385  0.709
2014 Rotblat B, Southwell AL, Ehrnhoefer DE, Skotte NH, Metzler M, Franciosi S, Leprivier G, Somasekharan SP, Barokas A, Deng Y, Tang T, Mathers J, Cetinbas N, Daugaard M, Kwok B, ... ... Hayden MR, et al. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proceedings of the National Academy of Sciences of the United States of America. 111: 3032-7. PMID 24516159 DOI: 10.1073/Pnas.1314421111  0.666
2014 Martin DD, Heit RJ, Yap MC, Davidson MW, Hayden MR, Berthiaume LG. Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. Human Molecular Genetics. 23: 3166-79. PMID 24459296 DOI: 10.1093/Hmg/Ddu027  0.405
2014 Lopes C, Ribeiro M, Duarte AI, Humbert S, Saudou F, Pereira de Almeida L, Hayden M, Rego AC. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. Molecular Neurobiology. 49: 1126-42. PMID 24347322 DOI: 10.1007/S12035-013-8585-5  0.421
2014 Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN, Sanders SS, Hayden MR, Raymond LA. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin. The Journal of Biological Chemistry. 289: 3518-28. PMID 24347167 DOI: 10.1074/Jbc.M113.513945  0.676
2014 Semaka A, Hayden MR. Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results Clinical Genetics. 85: 303-311. PMID 24256063 DOI: 10.1111/Cge.12324  0.763
2014 Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 105-14. PMID 24151181 DOI: 10.1002/Mds.25717  0.306
2014 Ehrnhoefer DE, Skotte NH, Ladha S, Nguyen YT, Qiu X, Deng Y, Huynh KT, Engemann S, Nielsen SM, Becanovic K, Leavitt BR, Hasholt L, Hayden MR. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Human Molecular Genetics. 23: 717-29. PMID 24070868 DOI: 10.1093/Hmg/Ddt458  0.361
2014 Kay C, Collins J, Skotte N, Southwell A, DiPardo A, Ross C, Squitieri F, Hayden M. M03 Complete Huntingtin Haplotypes For Allele-specific Silencing Journal of Neurology, Neurosurgery & Psychiatry. 85: A95-A95. DOI: 10.1136/Jnnp-2014-309032.275  0.68
2013 Stanek LM, Yang W, Angus S, Sardi PS, Hayden MR, Hung GH, Bennett CF, Cheng SH, Shihabuddin LS. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. Journal of Huntington's Disease. 2: 217-28. PMID 25063516 DOI: 10.3233/Jhd-130057  0.442
2013 Milnerwood AJ, Parsons MP, Young FB, Singaraja RR, Franciosi S, Volta M, Bergeron S, Hayden MR, Raymond LA. Memory and synaptic deficits in Hip14/DHHC17 knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 110: 20296-301. PMID 24277827 DOI: 10.1073/Pnas.1222384110  0.305
2013 Wan J, Savas JN, Roth AF, Sanders SS, Singaraja RR, Hayden MR, Yates JR, Davis NG. Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease. Chemistry & Biology. 20: 1421-34. PMID 24211138 DOI: 10.1016/J.Chembiol.2013.09.018  0.412
2013 Franciosi S, Shim Y, Lau M, Hayden MR, Leavitt BR. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1987-94. PMID 24142393 DOI: 10.1002/Mds.25663  0.337
2013 Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nature Reviews. Neuroscience. 14: 708-21. PMID 24052178 DOI: 10.1038/Nrn3570  0.647
2013 Semaka A, Kay C, Doty CN, Collins JA, Tam N, Hayden MR. High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 162: 864-71. PMID 24038799 DOI: 10.1002/Ajmg.B.32193  0.756
2013 Østergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN, Vaid K, Villanueva EB, Swayze EE, Bennett CF, Hayden MR, Seth PP. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS Nucleic Acids Research. 41: 9634-9650. PMID 23963702 DOI: 10.1093/Nar/Gkt725  0.707
2013 Houge G, Bruland O, Bjørnevoll I, Hayden MR, Semaka A. De novo Huntington disease caused by 26-44 CAG repeat expansion on a low-risk haplotype. Neurology. 81: 1099-100. PMID 23946314 DOI: 10.1212/Wnl.0B013E3182A4A4Af  0.765
2013 Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR. CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. Journal of Medical Genetics. 50: 696-703. PMID 23896435 DOI: 10.1136/Jmedgenet-2013-101796  0.765
2013 Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, et al. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nature Medicine. 19: 1030-8. PMID 23852340 DOI: 10.1038/Nm.3246  0.792
2013 Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, et al. Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics. 14: 173-9. PMID 23644918 DOI: 10.1007/S10048-013-0364-Y  0.37
2013 Brunham LR, Hayden MR. Hunting human disease genes: lessons from the past, challenges for the future. Human Genetics. 132: 603-17. PMID 23504071 DOI: 10.1007/S00439-013-1286-3  0.359
2013 Baine FK, Kay C, Ketelaar ME, Collins JA, Semaka A, Doty CN, Krause A, Greenberg LJ, Hayden MR. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. European Journal of Human Genetics : Ejhg. 21: 1120-7. PMID 23463025 DOI: 10.1038/Ejhg.2013.2  0.755
2013 Karasinska JM, de Haan W, Franciosi S, Ruddle P, Fan J, Kruit JK, Stukas S, Lütjohann D, Gutmann DH, Wellington CL, Hayden MR. ABCA1 influences neuroinflammation and neuronal death. Neurobiology of Disease. 54: 445-55. PMID 23376685 DOI: 10.1016/J.Nbd.2013.01.018  0.369
2013 Singaraja RR, Sivapalaratnam S, Hovingh K, Dubé MP, Castro-Perez J, Collins HL, Adelman SJ, Riwanto M, Manz J, Hubbard B, Tietjen I, Wong K, Mitnaul LJ, van Heek M, Lin L, ... ... Hayden MR, et al. The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. Circulation. Cardiovascular Genetics. 6: 54-62. PMID 23243195 DOI: 10.1161/Circgenetics.111.962613  0.305
2013 Sutton LM, Sanders SS, Butland SL, Singaraja RR, Franciosi S, Southwell AL, Doty CN, Schmidt ME, Mui KK, Kovalik V, Young FB, Zhang W, Hayden MR. Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. Human Molecular Genetics. 22: 452-65. PMID 23077216 DOI: 10.1093/Hmg/Dds441  0.735
2013 Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, Villanueva EB, Kovalik V, Xie Y, Pouladi MA, Collins JA, Yang XW, Franciosi S, Hayden MR. A fully humanized transgenic mouse model of Huntington disease. Human Molecular Genetics. 22: 18-34. PMID 23001568 DOI: 10.1093/Hmg/Dds397  0.827
2013 Semaka A, Balneaves LG, Hayden MR. "Grasping the grey": Patient understanding and interpretation of an intermediate allele predictive test result for huntington disease Journal of Genetic Counseling. 22: 200-217. PMID 22903792 DOI: 10.1007/S10897-012-9533-7  0.748
2012 Graham RK, Deng Y, Pouladi MA, Vaid K, Ehrnhoefer D, Southwell AL, Bissada N, Franciosi S, Hayden MR. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. Journal of Huntington's Disease. 1: 243-60. PMID 25063333 DOI: 10.3233/Jhd-120038  0.805
2012 Strong MK, Southwell AL, Yonan JM, Hayden MR, Macgregor GR, Thompson LM, Steward O. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. Journal of Huntington's Disease. 1: 221-41. PMID 23833693 DOI: 10.3233/Jhd-129005  0.707
2012 Southwell AL, Skotte NH, Bennett CF, Hayden MR. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine. 18: 634-43. PMID 23026741 DOI: 10.1016/J.Molmed.2012.09.001  0.711
2012 Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, et al. Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Human Genetics. 131: 1833-40. PMID 22825315 DOI: 10.1007/S00439-012-1205-Z  0.355
2012 Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Néri C, Hayden MR. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 48: 282-9. PMID 22796360 DOI: 10.1016/J.Nbd.2012.06.026  0.781
2012 Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, et al. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochemical and Biophysical Research Communications. 424: 404-8. PMID 22771793 DOI: 10.1016/J.Bbrc.2012.06.120  0.386
2012 Pouladi MA, Hayden MR. Polyglutamine diseases and the risk of cancer. The Lancet. Oncology. 13: 569-71. PMID 22652230 DOI: 10.1016/S1470-2045(12)70167-5  0.582
2012 Young FB, Franciosi S, Spreeuw A, Deng Y, Sanders S, Tam NC, Huang K, Singaraja RR, Zhang W, Bissada N, Kay C, Hayden MR. Low levels of human HIP14 are sufficient to rescue neuropathological, behavioural, and enzymatic defects due to loss of murine HIP14 in Hip14-/- mice. Plos One. 7: e36315. PMID 22649491 DOI: 10.1371/Journal.Pone.0036315  0.365
2012 Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Griguoli A, Di Donato S, Gomez-Tortosa E, Ayuso C, et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. American Journal of Human Genetics. 90: 434-44. PMID 22387017 DOI: 10.1016/J.Ajhg.2012.01.005  0.381
2012 Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Human Molecular Genetics. 21: 2219-32. PMID 22328089 DOI: 10.1093/Hmg/Dds037  0.796
2012 Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 78: 690-5. PMID 22323755 DOI: 10.1212/Wnl.0B013E318249F683  0.353
2012 Uribe V, Wong BK, Graham RK, Cusack CL, Skotte NH, Pouladi MA, Xie Y, Feinberg K, Ou Y, Ouyang Y, Deng Y, Franciosi S, Bissada N, Spreeuw A, Zhang W, ... ... Hayden MR, et al. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Human Molecular Genetics. 21: 1954-67. PMID 22262731 DOI: 10.1093/Hmg/Dds005  0.785
2012 Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Bottorff JL, Hayden MR. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 159: 217-26. PMID 22231990 DOI: 10.1002/Ajmg.B.32016  0.313
2012 Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, Graham RK, Hayden MR, Hou Z, Mori S, Swing D, Pletnikov M, Duan W, Tessarollo L, Ross CA. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 183-93. PMID 22219281 DOI: 10.1523/Jneurosci.1305-11.2012  0.699
2012 Young FB, Butland SL, Sanders SS, Sutton LM, Hayden MR. Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases. Progress in Neurobiology. 97: 220-38. PMID 22155432 DOI: 10.1016/J.Pneurobio.2011.11.002  0.421
2012 Franciosi S, Ryu JK, Shim Y, Hill A, Connolly C, Hayden MR, McLarnon JG, Leavitt BR. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 45: 438-49. PMID 21946335 DOI: 10.1016/J.Nbd.2011.09.003  0.374
2012 Bombard Y, Semaka A, Hayden MR. Adoption and the communication of genetic risk: Experiences in Huntington disease Clinical Genetics. 81: 64-69. PMID 21204796 DOI: 10.1111/J.1399-0004.2010.01614.X  0.708
2011 Graham RK, Ehrnhoefer DE, Hayden MR. Caspase-6 and neurodegeneration. Trends in Neurosciences. 34: 646-56. PMID 22018804 DOI: 10.1016/J.Tins.2011.09.001  0.649
2011 Ehrnhoefer DE, Wong BK, Hayden MR. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nature Reviews. Drug Discovery. 10: 853-67. PMID 22015920 DOI: 10.1038/Nrd3556  0.38
2011 Ding Y, Zhang L, Wang Y, Huang W, Tang Y, Bai L, Ross CJ, Hayden MR, Liu G. Amelioration of hypertriglyceridemia with hypo-alpha-cholesterolemia in LPL deficient mice by hematopoietic cell-derived LPL. Plos One. 6: e25620. PMID 21980507 DOI: 10.1371/Journal.Pone.0025620  0.338
2011 Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 2178-85. PMID 21971427 DOI: 10.1038/Mt.2011.201  0.821
2011 Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease Nature Reviews Neurology. 7: 561-572. PMID 21894212 DOI: 10.1038/Nrneurol.2011.132  0.374
2011 Carroll JB, Southwell AL, Graham RK, Lerch JP, Ehrnhoefer DE, Cao LP, Zhang WN, Deng Y, Bissada N, Henkelman RM, Hayden MR. Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Molecular Neurodegeneration. 6: 59. PMID 21854568 DOI: 10.1186/1750-1326-6-59  0.821
2011 Singaraja RR, Huang K, Sanders SS, Milnerwood AJ, Hines R, Lerch JP, Franciosi S, Drisdel RC, Vaid K, Young FB, Doty C, Wan J, Bissada N, Henkelman RM, Green WN, ... ... Hayden MR, et al. Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Human Molecular Genetics. 20: 3899-909. PMID 21775500 DOI: 10.1093/Hmg/Ddr308  0.386
2011 Huang K, Sanders SS, Kang R, Carroll JB, Sutton L, Wan J, Singaraja R, Young FB, Liu L, El-Husseini A, Davis NG, Hayden MR. Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14. Human Molecular Genetics. 20: 3356-65. PMID 21636527 DOI: 10.1093/Hmg/Ddr242  0.732
2011 Brunham LR, Tietjen I, Bochem AE, Singaraja RR, Franchini PL, Radomski C, Mattice M, Legendre A, Hovingh GK, Kastelein JJ, Hayden MR. Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clinical Genetics. 79: 575-81. PMID 21480869 DOI: 10.1111/J.1399-0004.2011.01682.X  0.316
2011 Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiology of Disease. 43: 257-65. PMID 21458571 DOI: 10.1016/J.Nbd.2011.03.018  0.733
2011 Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, Bossy B, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nature Medicine. 17: 377-82. PMID 21336284 DOI: 10.1038/Nm.2313  0.66
2011 Ehrnhoefer DE, Sutton L, Hayden MR. Small changes, big impact: Posttranslational modifications and function of huntingtin in huntington disease Neuroscientist. 17: 475-492. PMID 21311053 DOI: 10.1177/1073858410390378  0.416
2011 Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, Hayden AR, Kanazawa I, Ross CJ, Hayden MR. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. European Journal of Human Genetics : Ejhg. 19: 561-6. PMID 21248742 DOI: 10.1038/Ejhg.2010.229  0.329
2011 Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, Christie BR. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiology of Disease. 41: 249-60. PMID 20875859 DOI: 10.1016/J.Nbd.2010.09.012  0.659
2011 Petrilli⁎ AM, Song W, Bossy B, Liot G, Lubitz S, de Assis V, Johnson J, Poquiz P, Tjong J, Pouladi M, Hayden MR, Masliah E, Ellisman M, Rouiller I, Perkins G, et al. Mutant Huntington interaction with DRP1 impairs the mitochondrial fission and fusion balance and mediates neuronal injury Mitochondrion. 11: 649. DOI: 10.1016/J.Mito.2011.03.045  0.584
2010 Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, Metzler M, Bissada N, Wang L, Faull RL, Gray M, Yang XW, Raymond LA, Hayden MR. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 15019-29. PMID 21068307 DOI: 10.1523/Jneurosci.2071-10.2010  0.777
2010 Sturrock A, Laule C, Decolongon J, Dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 75: 1702-10. PMID 21060093 DOI: 10.1212/Wnl.0B013E3181Fc27E4  0.354
2010 Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 14708-18. PMID 21048129 DOI: 10.1523/Jneurosci.1637-10.2010  0.401
2010 Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, Lu G, Leavitt BR, Hayden MR. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 14318-29. PMID 20980587 DOI: 10.1523/Jneurosci.1589-10.2010  0.696
2010 Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O, MacDonald M, Wellington C, DiDonato S, Hayden M, Cattaneo E. Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 10844-50. PMID 20702713 DOI: 10.1523/Jneurosci.0917-10.2010  0.791
2010 Huang K, Kang MH, Askew C, Kang R, Sanders SS, Wan J, Davis NG, Hayden MR. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 40: 207-15. PMID 20685337 DOI: 10.1016/J.Nbd.2010.05.027  0.372
2010 Williams JK, Erwin C, Juhl AR, Mengeling M, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS. In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1150-9. PMID 20468062 DOI: 10.1002/Ajmg.B.31080  0.302
2010 Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS. Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1081-93. PMID 20468061 DOI: 10.1002/Ajmg.B.31079  0.321
2010 Acuña-Alonzo V, Flores-Dorantes T, Kruit JK, Villarreal-Molina T, Arellano-Campos O, Hünemeier T, Moreno-Estrada A, Ortiz-López MG, Villamil-Ramírez H, León-Mimila P, Villalobos-Comparan M, Jacobo-Albavera L, Ramírez-Jiménez S, Sikora M, Zhang LH, ... ... Hayden MR, et al. A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Human Molecular Genetics. 19: 2877-85. PMID 20418488 DOI: 10.1093/Hmg/Ddq173  0.305
2010 Ding YL, Wang YH, Huang W, Liu G, Ross C, Hayden MR, Yang JK. Glucose intolerance and decreased early insulin response in mice with severe hypertriglyceridemia. Experimental Biology and Medicine (Maywood, N.J.). 235: 40-6. PMID 20404017 DOI: 10.1258/Ebm.2009.009100  0.305
2010 Chung S, Timmins JM, Duong M, Degirolamo C, Rong S, Sawyer JK, Singaraja RR, Hayden MR, Maeda N, Rudel LL, Shelness GS, Parks JS. Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism. The Journal of Biological Chemistry. 285: 12197-209. PMID 20178985 DOI: 10.1074/Jbc.M109.096933  0.32
2010 Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 65: 178-90. PMID 20152125 DOI: 10.1016/J.Neuron.2010.01.008  0.797
2010 Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Human Molecular Genetics. 19: 1528-38. PMID 20097678 DOI: 10.1093/Hmg/Ddq026  0.748
2010 Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, Hayden MR, Leavitt BR. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Human Molecular Genetics. 19: 1438-52. PMID 20089533 DOI: 10.1093/Hmg/Ddq018  0.635
2010 Glier MB, Pissios P, Babich SL, Macdonald ML, Hayden MR, Maratos-Flier E, Gibson WT. The metabolic phenotype of SCD1-deficient mice is independent of melanin-concentrating hormone. Peptides. 31: 123-9. PMID 19883709 DOI: 10.1016/J.Peptides.2009.10.018  0.319
2010 Semaka A, Collins JA, Hayden MR. Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 314-20. PMID 19455596 DOI: 10.1002/Ajmg.B.30970  0.765
2010 Sturrock A, Laule C, Decolongon J, dar Santos R, Coleman AJ, Creighton S, Bechtel N, Reilmann R, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. H06 Cross sectional and longitudinal 3T magnetic resonance spectroscopy in a TRACK-HD cohort of individuals with premanifest and early Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A35.2-A35. DOI: 10.1136/Jnnp.2010.222653.6  0.311
2010 Pouladi MA, Brilluad E, Xie Y, Franciosi S, Zhang W, Zapala M, Compte E, Poucheret P, Maurel J, Néri C, Hayden MR. B13 NP03, a low dose lithium microemulsion, improves motor function and rescues striatal pathology without toxicity in the YAC128 mouse model of Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A15.1-A15. DOI: 10.1136/Jnnp.2010.222596.13  0.633
2010 Pouladi MA, Carroll J, dar Santos R, Bertram L, Hayden MR. B12 Treatment with arimoclomol does not lead to rescue of motor or striatal deficits in the YAC128 mouse model of Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A14.2-A14. DOI: 10.1136/Jnnp.2010.222596.12  0.792
2010 Graham RK, Deng Y, Pouladi MA, Vaid K, Xie Y, Bissada N, Franciosi S, Hayden MR. A04 Caspase 6 resistant mutant huntingtin does not rescue the toxic effects of caspase cleavable mutant huntingtin in vivo Journal of Neurology, Neurosurgery & Psychiatry. 81: A2.1-A2. DOI: 10.1136/Jnnp.2010.222570.4  0.777
2010 Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RWY, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice (DOI:10.1016/j.neuron.2010.01.008) Neuron. 65: 436. DOI: 10.1016/j.neuron.2010.01.031  0.753
2010 Kruit JK, Brunham LR, Verchere CB, Hayden MR. Cholesterol toxicity in pancreatic islets from LDL receptor-deficient mice. Reply to: De Souza JC, de Oliveira CAM, Carneiro em et al. [letter] Diabetologia. 53: 2463-2464. DOI: 10.1007/S00125-010-1877-7  0.341
2009 Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. The Journal of Cell Biology. 187: 1083-99. PMID 20026656 DOI: 10.1083/Jcb.200909067  0.586
2009 Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine. 15: 1407-13. PMID 19915593 DOI: 10.1038/Nm.2056  0.769
2009 Fan J, Cowan CM, Zhang LY, Hayden MR, Raymond LA. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 10928-38. PMID 19726651 DOI: 10.1523/Jneurosci.2491-09.2009  0.402
2009 Macdonald ML, Bissada N, Vallance BA, Hayden MR. Absence of stearoyl-CoA desaturase-1 does not promote DSS-induced acute colitis. Biochimica Et Biophysica Acta. 1791: 1166-72. PMID 19695343 DOI: 10.1016/J.Bbalip.2009.08.001  0.343
2009 Yeretssian G, Doiron K, Shao W, Leavitt BR, Hayden MR, Nicholson DW, Saleh M. Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proceedings of the National Academy of Sciences of the United States of America. 106: 9016-20. PMID 19447924 DOI: 10.1073/Pnas.0813362106  0.317
2009 Xian X, Liu T, Yu J, Wang Y, Miao Y, Zhang J, Yu Y, Ross C, Karasinska JM, Hayden MR, Liu G, Chui D. Presynaptic defects underlying impaired learning and memory function in lipoprotein lipase-deficient mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 4681-5. PMID 19357293 DOI: 10.1523/Jneurosci.0297-09.2009  0.351
2009 Karasinska JM, Rinninger F, Lütjohann D, Ruddle P, Franciosi S, Kruit JK, Singaraja RR, Hirsch-Reinshagen V, Fan J, Brunham LR, Bissada N, Ramakrishnan R, Wellington CL, Parks JS, Hayden MR. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function Journal of Neuroscience. 29: 3579-3589. PMID 19295162 DOI: 10.1523/Jneurosci.4741-08.2009  0.314
2009 Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR. Mouse models of Huntington disease: Variations on a theme Dmm Disease Models and Mechanisms. 2: 123-129. PMID 19259385 DOI: 10.1242/Dmm.002451  0.661
2009 Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. American Journal of Human Genetics. 84: 351-66. PMID 19249009 DOI: 10.1016/J.Ajhg.2009.02.003  0.811
2009 Joshi PR, Wu NP, André VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2414-27. PMID 19244517 DOI: 10.1523/Jneurosci.5687-08.2009  0.741
2009 Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2193-204. PMID 19228972 DOI: 10.1523/Jneurosci.5473-08.2009  0.829
2009 Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain : a Journal of Neurology. 132: 919-32. PMID 19224899 DOI: 10.1093/Brain/Awp006  0.766
2009 Ratovitski T, Gucek M, Jiang H, Chighladze E, Waldron E, D'Ambola J, Hou Z, Liang Y, Poirier MA, Hirschhorn RR, Graham R, Hayden MR, Cole RN, Ross CA. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. The Journal of Biological Chemistry. 284: 10855-67. PMID 19204007 DOI: 10.1074/Jbc.M804813200  0.671
2009 Vaessen SF, Dallinga-Thie GM, Ross CJ, Splint LJ, Castellani LW, Rensen PC, Hayden MR, Schaap FG, Kuivenhoven JA. Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels. Journal of Lipid Research. 50: 880-4. PMID 19141870 DOI: 10.1194/Jlr.M800551-Jlr200  0.33
2009 MacDonald ML, van Eck M, Hildebrand RB, Wong BW, Bissada N, Ruddle P, Kontush A, Hussein H, Pouladi MA, Chapman MJ, Fievet C, van Berkel TJ, Staels B, McManus BM, Hayden MR. Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 29: 341-7. PMID 19095997 DOI: 10.1161/Atvbaha.108.181099  0.605
2009 Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Molecular and Cellular Neurosciences. 40: 121-7. PMID 18992820 DOI: 10.1016/J.Mcn.2008.09.007  0.683
2009 Wang Y, Sternfeld L, Yang F, Rodriguez JA, Ross C, Hayden MR, Carriere F, Liu G, Hofer W, Schulz I. Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells Gut. 58: 422-430. PMID 18936103 DOI: 10.1136/Gut.2007.146258  0.301
2009 Frohlich J, Hoag G, McLEOD R, Hayden M, Godin DV, Wadsworth LD, Critchley JD, Pritchard PH. Hypoalphalipoproteinemia resembling fish eye disease. Acta Medica Scandinavica. 221: 291-298. PMID 3591467 DOI: 10.1111/J.0954-6820.1987.Tb00896.X  0.302
2009 Gil-Mohapel J, Simpson J, Pouladi M, Hayden M, Christie B. Evaluation of Hippocampal Neurogenesis in YAC128 Huntington’s Disease Transgenic Mice European Psychiatry. 24: 1-1. DOI: 10.1016/S0924-9338(09)71153-8  0.663
2008 Cowan CM, Fan MM, Fan J, Shehadeh J, Zhang LY, Graham RK, Hayden MR, Raymond LA. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 12725-35. PMID 19036965 DOI: 10.1523/Jneurosci.4619-08.2008  0.696
2008 Yang F, Wang Y, Sternfeld L, Rodriguez JA, Ross C, Hayden MR, Carriere F, Liu G, Schulz I. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiologica (Oxford, England). 195: 13-28. PMID 18983441 DOI: 10.1111/J.1748-1716.2008.01933.X  0.31
2008 Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine. 205: 1869-77. PMID 18625748 DOI: 10.1084/Jem.20080178  0.631
2008 Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, Li S, Chan AW, Li XJ. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Human Molecular Genetics. 17: 2738-51. PMID 18558632 DOI: 10.1093/Hmg/Ddn175  0.718
2008 Semaka A, Warby S, Leavitt BR, Hayden MR. Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1794-5; author reply. PMID 18548612 DOI: 10.1002/mds.21820  0.735
2008 Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiology of Disease. 31: 80-8. PMID 18502655 DOI: 10.1016/J.Nbd.2008.03.010  0.817
2008 Warby SC, Doty CN, Graham RK, Carroll JB, Yang YZ, Singaraja RR, Overall CM, Hayden MR. Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Human Molecular Genetics. 17: 2390-404. PMID 18445618 DOI: 10.1093/Hmg/Ddn139  0.785
2008 Lerch JP, Carroll JB, Dorr A, Spring S, Evans AC, Hayden MR, Sled JG, Henkelman RM. Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. Neuroimage. 41: 243-51. PMID 18387826 DOI: 10.1016/J.Neuroimage.2008.02.019  0.702
2008 Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, ... Hayden M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery, and Psychiatry. 79: 874-80. PMID 18096682 DOI: 10.1136/Jnnp.2007.128728  0.365
2008 Zhang X, Qi R, Xian X, Yang F, Blackstein M, Deng X, Fan J, Ross C, Karasinska J, Hayden MR, Liu G. Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circulation Research. 102: 250-6. PMID 18032735 DOI: 10.1161/Circresaha.107.156554  0.355
2008 Fan MM, Zhang H, Hayden MR, Pelech SL, Raymond LA. Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors. Journal of Neurochemistry. 104: 790-805. PMID 17971125 DOI: 10.1111/J.1471-4159.2007.05016.X  0.358
2008 MacDonald ML, Singaraja RR, Bissada N, Ruddle P, Watts R, Karasinska JM, Gibson WT, Fievet C, Vance JE, Staels B, Hayden MR. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. Journal of Lipid Research. 49: 217-29. PMID 17960025 DOI: 10.1194/Jlr.M700478-Jlr200  0.308
2008 Bombard Y, Penziner E, Suchowersky O, Guttman M, Paulsen JS, Bottorff JL, Hayden MR. Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. European Journal of Human Genetics : Ejhg. 16: 279-89. PMID 17957229 DOI: 10.1038/Sj.Ejhg.5201937  0.308
2008 Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM. Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage. 39: 32-9. PMID 17942324 DOI: 10.1016/J.Neuroimage.2007.08.033  0.724
2008 Young FB, Deng DY, Singaraja RR, Hayden MR. REGULATION OF HUNTINGTIN PALITOYLATION AND ITS ROLE IN HUNTINGTON DISEASE Clinical & Investigative Medicine. 31: 26. DOI: 10.25011/Cim.V31I4.4834  0.442
2008 Wild EJ, Björkqvist M, Thiele J, Silvestroni A, Soulet D, Magnusson A, Benn CL, Woodman B, André R, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, et al. P3-377: A novel pathogenic pathway of immune activation detectable before cinical onset in Huntington's disease Alzheimer's & Dementia. 4: T632-T632. DOI: 10.1016/J.Jalz.2008.05.1947  0.598
2008 Yeretssian G, Hayden MR, Nicholson DW, Saleh M. 50 A humanized BAC transgenic/knockout mouse model for human caspase-12 polymorphism Cytokine. 43: 248. DOI: 10.1016/J.Cyto.2008.07.091  0.314
2007 Orban P, Devon RS, Hayden MR, Leavitt BR. Chapter 15 Juvenile amyotrophic lateral sclerosis. Handbook of Clinical Neurology. 82: 301-12. PMID 18808900 DOI: 10.1016/S0072-9752(07)80018-2  0.359
2007 Ratovitski T, Nakamura M, D'Ambola J, Chighladze E, Liang Y, Wang W, Graham R, Hayden MR, Borchelt DR, Hirschhorn RR, Ross CA. N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle (Georgetown, Tex.). 6: 2970-81. PMID 18156806 DOI: 10.4161/Cc.6.23.4992  0.678
2007 Fernandes HB, Baimbridge KG, Church J, Hayden MR, Raymond LA. Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 13614-23. PMID 18077673 DOI: 10.1523/Jneurosci.3455-07.2007  0.337
2007 Parker JA, Metzler M, Georgiou J, Mage M, Roder JC, Rose AM, Hayden MR, Néri C. Huntingtin-interacting protein 1 influences worm and mouse presynaptic function and protects Caenorhabditis elegans neurons against mutant polyglutamine toxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 11056-64. PMID 17928447 DOI: 10.1523/Jneurosci.1941-07.2007  0.36
2007 Valenza M, Carroll JB, Leoni V, Bertram LN, Björkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human Molecular Genetics. 16: 2187-98. PMID 17613541 DOI: 10.1093/Hmg/Ddm170  0.748
2007 Benn CL, Slow EJ, Farrell LA, Graham R, Deng Y, Hayden MR, Cha JH. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience. 147: 354-72. PMID 17544587 DOI: 10.1016/J.Neuroscience.2007.03.010  0.797
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/Hmg/Ddm133  0.686
2007 Butland SL, Devon RS, Huang Y, Mead CL, Meynert AM, Neal SJ, Lee SS, Wilkinson A, Yang GS, Yuen MM, Hayden MR, Holt RA, Leavitt BR, Ouellette BF. CAG-encoded polyglutamine length polymorphism in the human genome. Bmc Genomics. 8: 126. PMID 17519034 DOI: 10.1186/1471-2164-8-126  0.379
2007 Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR, Leavitt BR. Testicular degeneration in Huntington disease. Neurobiology of Disease. 26: 512-20. PMID 17433700 DOI: 10.1016/J.Nbd.2007.01.006  0.729
2007 Fan MM, Fernandes HB, Zhang LY, Hayden MR, Raymond LA. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 3768-79. PMID 17409241 DOI: 10.1523/Jneurosci.4356-06.2007  0.417
2007 Van Raamsdonk JM, Warby SC, Hayden MR. Selective degeneration in YAC mouse models of Huntington disease Brain Research Bulletin. 72: 124-131. PMID 17352936 DOI: 10.1016/J.Brainresbull.2006.10.018  0.729
2007 Metzler M, Gan L, Wong TP, Liu L, Helm J, Liu L, Georgiou J, Wang Y, Bissada N, Cheng K, Roder JC, Wang YT, Hayden MR. NMDA receptor function and NMDA receptor-dependent phosphorylation of huntingtin is altered by the endocytic protein HIP1. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 2298-308. PMID 17329427 DOI: 10.1523/Jneurosci.5175-06.2007  0.324
2007 Bombard Y, Penziner E, Decolongon J, Klimek ML, Creighton S, Suchowersky O, Guttman M, Paulsen JS, Bottorff JL, Hayden MR. Managing genetic discrimination: strategies used by individuals found to have the Huntington disease mutation. Clinical Genetics. 71: 220-31. PMID 17309644 DOI: 10.1111/J.1399-0004.2007.00770.X  0.323
2007 Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, Ross CA, Beglinger L, Hayden MR, Kieburtz K, Kayson E, Julian-Baros E, Duff K, Guttman M, Nance M, et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia. 45: 1767-76. PMID 17303196 DOI: 10.1016/J.Neuropsychologia.2006.12.015  0.309
2007 Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease. 26: 189-200. PMID 17276692 DOI: 10.1016/J.Nbd.2006.12.010  0.796
2007 Hirsch-Reinshagen V, Chan JY, Wilkinson A, Tanaka T, Fan J, Ou G, Maia LF, Singaraja RR, Hayden MR, Wellington CL. Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-β peptide levels in vivo Journal of Lipid Research. 48: 914-923. PMID 17235115 DOI: 10.1194/Jlr.M600543-Jlr200  0.342
2007 Khatchadourian K, Smith CE, Metzler M, Gregory M, Hayden MR, Cyr DG, Hermo L. Structural abnormalities in spermatids together with reduced sperm counts and motility underlie the reproductive defect in HIP1-/- mice. Molecular Reproduction and Development. 74: 341-59. PMID 16967501 DOI: 10.1002/Mrd.20564  0.345
2006 Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. Bmc Neuroscience. 7: 80. PMID 17147801 DOI: 10.1186/1471-2202-7-80  0.708
2006 Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR, Friedlander RM. Huntingtin inhibits caspase-3 activation. The Embo Journal. 25: 5896-906. PMID 17124493 DOI: 10.1038/Sj.Emboj.7601445  0.675
2006 Oliveira JM, Chen S, Almeida S, Riley R, Gonçalves J, Oliveira CR, Hayden MR, Nicholls DG, Ellerby LM, Rego AC. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 11174-86. PMID 17065457 DOI: 10.1523/Jneurosci.3004-06.2006  0.312
2006 Houde C, Dickinson RJ, Houtzager VM, Cullum R, Montpetit R, Metzler M, Simpson EM, Roy S, Hayden MR, Hoodless PA, Nicholson DW. Hippi is essential for node cilia assembly and Sonic hedgehog signaling. Developmental Biology. 300: 523-33. PMID 17027958 DOI: 10.1016/J.Ydbio.2006.09.001  0.306
2006 Leavitt BR, Hayden MR. Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease? Nature Clinical Practice. Neurology. 2: 536-7. PMID 16990826 DOI: 10.1038/Ncpneuro0299  0.33
2006 Semaka A, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clinical Genetics. 70: 283-94. PMID 16965319 DOI: 10.1111/J.1399-0004.2006.00668.X  0.772
2006 Kishikawa S, Li JL, Gillis T, Hakky MM, Warby S, Hayden M, MacDonald ME, Myers RH, Gusella JF. Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntington's disease. Neurobiology of Disease. 24: 280-5. PMID 16962786 DOI: 10.1016/J.Nbd.2006.07.008  0.352
2006 Brunham LR, Kruit JK, Pape TD, Parks JS, Kuipers F, Hayden MR. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circulation Research. 99: 672-4. PMID 16946132 DOI: 10.1161/01.Res.0000244014.19589.8E  0.32
2006 Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross CA, Margolis RL, Rosenblatt A, Squitieri F, Frati L, Gómez-Tortosa E, García CA, Suchowersky O, Klimek ML, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. Bmc Medical Genetics. 7: 71. PMID 16914060 DOI: 10.1186/1471-2350-7-71  0.334
2006 Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, Westaway D, Wellington CL. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiology of Disease. 24: 114-27. PMID 16899370 DOI: 10.1016/J.Nbd.2006.06.007  0.308
2006 Alvarez C, Tredwell S, Vera MD, Hayden M. The genotype-phenotype correlation of hereditary multiple exostoses. Clinical Genetics. 70: 122-130. PMID 16879194 DOI: 10.1111/J.1399-0004.2006.00653.X  0.301
2006 Singaraja RR, Visscher H, James ER, Chroni A, Coutinho JM, Brunham LR, Kang MH, Zannis VI, Chimini G, Hayden MR. Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circulation Research. 99: 389-97. PMID 16873719 DOI: 10.1161/01.Res.0000237920.70451.Ad  0.335
2006 Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends in Genetics : Tig. 22: 408-11. PMID 16806565 DOI: 10.1016/J.Tig.2006.05.008  0.806
2006 Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, ... ... Hayden MR, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 125: 1179-91. PMID 16777606 DOI: 10.1016/J.Cell.2006.04.026  0.818
2006 Devon RS, Orban PC, Gerrow K, Barbieri MA, Schwab C, Cao LP, Helm JR, Bissada N, Cruz-Aguado R, Davidson TL, Witmer J, Metzler M, Lam CK, Tetzlaff W, Simpson EM, ... ... Hayden MR, et al. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proceedings of the National Academy of Sciences of the United States of America. 103: 9595-600. PMID 16769894 DOI: 10.1073/Pnas.0510197103  0.391
2006 Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E. Preparing for preventive clinical trials: the Predict-HD study. Archives of Neurology. 63: 883-90. PMID 16769871 DOI: 10.1001/Archneur.63.6.883  0.37
2006 Ross CJ, Twisk J, Bakker AC, Miao F, Verbart D, Rip J, Godbey T, Dijkhuizen P, Hermens WT, Kastelein JJ, Kuivenhoven JA, Meulenberg JM, Hayden MR. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Human Gene Therapy. 17: 487-99. PMID 16716106 DOI: 10.1089/Hum.2006.17.487  0.304
2006 Brunham LR, Singaraja RR, Hayden MR. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis Annual Review of Nutrition. 26: 105-129. PMID 16704350 DOI: 10.1146/Annurev.Nutr.26.061505.111214  0.309
2006 Yanai A, Huang K, Kang R, Singaraja RR, Arstikaitis P, Gan L, Orban PC, Mullard A, Cowan CM, Raymond LA, Drisdel RC, Green WN, Ravikumar B, Rubinsztein DC, El-Husseini A, ... Hayden MR, et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nature Neuroscience. 9: 824-31. PMID 16699508 DOI: 10.1038/Nn1702  0.388
2006 Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease. 23: 190-7. PMID 16697652 DOI: 10.1016/J.Nbd.2006.02.011  0.817
2006 Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJ, Stroes ES, Kuivenhoven JA. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arteriosclerosis, Thrombosis, and Vascular Biology. 26: 1236-45. PMID 16574898 DOI: 10.1161/01.Atv.0000219283.10832.43  0.35
2006 Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. Body weight is modulated by levels of full-length huntingtin. Human Molecular Genetics. 15: 1513-23. PMID 16571604 DOI: 10.1093/Hmg/Ddl072  0.663
2006 Bae BI, Hara MR, Cascio MB, Wellington CL, Hayden MR, Ross CA, Ha HC, Li XJ, Snyder SH, Sawa A. Mutant huntingtin: nuclear translocation and cytotoxicity mediated by GAPDH. Proceedings of the National Academy of Sciences of the United States of America. 103: 3405-9. PMID 16492755 DOI: 10.1073/Pnas.0511316103  0.331
2006 Zhao T, Guo J, Li H, Huang W, Xian X, Ross CJ, Hayden MR, Wen Z, Liu G. Hemorheological abnormalities in lipoprotein lipase deficient mice with severe hypertriglyceridemia. Biochemical and Biophysical Research Communications. 341: 1066-71. PMID 16460682 DOI: 10.1016/J.Bbrc.2006.01.067  0.323
2006 Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR. Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry. 96: 1121-9. PMID 16417581 DOI: 10.1111/J.1471-4159.2005.03605.X  0.799
2006 Rip J, Nierman MC, Sierts JA, Petersen W, Van den Oever K, Van Raalte D, Ross CJ, Hayden MR, Bakker AC, Dijkhuizen P, Hermens WT, Twisk J, Stroes E, Kastelein JJ, Kuivenhoven JA, et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Human Gene Therapy. 16: 1276-86. PMID 16259561 DOI: 10.1089/Hum.2005.16.1276  0.346
2006 Graham RK, Slow EJ, Deng Y, Bissada N, Lu G, Pearson J, Shehadeh J, Leavitt BR, Raymond LA, Hayden MR. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiology of Disease. 21: 444-55. PMID 16230019 DOI: 10.1016/J.Nbd.2005.08.007  0.835
2006 Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiology of Disease. 21: 392-403. PMID 16165367 DOI: 10.1016/J.Nbd.2005.08.001  0.691
2006 Hirsch-Reinshagen V, Chan JY, McIsaac SA, Naus KE, Maia LF, Burgess BL, Singaraja RR, Hayden MR, Wellington CL. P1-053: Alzheimer’s disease neuropathology is not mitigated by the physiological expression of human ABCA1 in APP/PS1 mice Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.428  0.376
2006 Pouladi MA, Bezprozvanny I, Raymond LA, Hayden MR. Molecular pathogenesis of Huntington's disease: The role of excitotoxicity Genetic Instabilities and Neurological Diseases, Second Edition. 251-260. DOI: 10.1016/B978-012369462-1/50016-8  0.583
2005 Brunham LR, Singaraja RR, Pape TD, Kejariwal A, Thomas PD, Hayden MR. Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene. Plos Genetics. 1: e83. PMID 16429166 DOI: 10.1371/Journal.Pgen.0010083  0.314
2005 Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 3823-35. PMID 16278236 DOI: 10.1093/Hmg/Ddi407  0.821
2005 Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. The Journal of Biological Chemistry. 280: 43243-56. PMID 16207707 DOI: 10.1074/Jbc.M508781200  0.349
2005 Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry. 95: 210-20. PMID 16181425 DOI: 10.1111/J.1471-4159.2005.03357.X  0.719
2005 van Leuven SI, Kastelein JJ, Hayden MR, d'Cruz D, Hughes GR, Stroes ES. Cardiovascular disease in systemic lupus erythematosus: has the time for action come? Current Opinion in Lipidology. 16: 501-6. PMID 16148533 DOI: 10.1097/01.Mol.0000182533.19135.Cb  0.307
2005 Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Journal of Neurochemistry. 95: 553-62. PMID 16135087 DOI: 10.1111/J.1471-4159.2005.03411.X  0.402
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology. 196: 266-72. PMID 16129433 DOI: 10.1016/J.Expneurol.2005.07.021  0.71
2005 Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proceedings of the National Academy of Sciences of the United States of America. 102: 11402-7. PMID 16076956 DOI: 10.1073/Pnas.0503634102  0.82
2005 Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 65: 286-92. PMID 16043801 DOI: 10.1212/01.Wnl.0000169025.09670.6D  0.322
2005 Ross CJ, Liu G, Kuivenhoven JA, Twisk J, Rip J, van Dop W, Excoffon KJ, Lewis SM, Kastelein JJ, Hayden MR. Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arteriosclerosis, Thrombosis, and Vascular Biology. 25: 2143-50. PMID 16002740 DOI: 10.1161/01.Atv.0000176971.27302.B0  0.374
2005 Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of Neurochemistry. 94: 1087-101. PMID 15992377 DOI: 10.1111/J.1471-4159.2005.03255.X  0.691
2005 Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 4169-80. PMID 15843620 DOI: 10.1523/Jneurosci.0590-05.2005  0.803
2005 Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, Crocker SF, Robertson HA, Hayden MR. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Human Molecular Genetics. 14: 1569-77. PMID 15843398 DOI: 10.1093/Hmg/Ddi165  0.377
2005 Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. The Journal of Clinical Investigation. 115: 1333-42. PMID 15841208 DOI: 10.1172/Jci23915  0.316
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 1379-92. PMID 15829505 DOI: 10.1093/Hmg/Ddi147  0.71
2005 Coutinho JM, Singaraja RR, Kang M, Arenillas DJ, Bertram LN, Bissada N, Staels B, Fruchart JC, Fievet C, Joseph-George AM, Wasserman WW, Hayden MR. Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis. Journal of Lipid Research. 46: 1113-23. PMID 15772424 DOI: 10.1194/Jlr.M400506-Jlr200  0.372
2005 Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinás R, Kristal BS, Hayden MR, Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 102: 2602-7. PMID 15695335 DOI: 10.1073/Pnas.0409402102  0.708
2005 Devon RS, Schwab C, Topp JD, Orban PC, Yang YZ, Pape TD, Helm JR, Davidson TL, Rogers DA, Gros-Louis F, Rouleau G, Horazdovsky BF, Leavitt BR, Hayden MR. Cross-species characterization of the ALS2 gene and analysis of its pattern of expression in development and adulthood. Neurobiology of Disease. 18: 243-57. PMID 15686953 DOI: 10.1016/J.Nbd.2004.10.002  0.373
2005 Guan JZ, Tamasawa N, Brunham LR, Matsui J, Murakami H, Suda T, Ochiai S, Tsutsui M, Kudou K, Satoh K, Hayden MR. A case of Tangier disease with a novel mutation in the C-terminal region of ATP-binding cassette transporter A1. American Journal of Medical Genetics. Part A. 398-401. PMID 15384103 DOI: 10.1002/Ajmg.A.30284  0.329
2005 Paulsen JS, Stout JC, Aylward E, Kieburtz K, Langbehn D, Ross C, Hayden M, Guttman M, Nance M, Oakes D. [P-058]: Early detection of dementia in Huntington's disease: The Predict-HD study Alzheimer's & Dementia. 1: S26-S26. DOI: 10.1016/J.Jalz.2005.06.132  0.313
2005 Van Raamsdonk JM, Hayden MR, Leavitt BR. Experimental models of Huntington's disease Drug Discovery Today: Disease Models. 2: 291-297. DOI: 10.1016/J.Ddmod.2005.11.010  0.365
2004 Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O'Hearn E, Ross CA, Seltzer WK, Walker RH, Ashizawa T, Rasmussen A, Hayden M, Almqvist EW, Harris J, Fahn S, MacDonald ME, et al. Huntington's Disease-like 2 (HDL2) in North America and Japan. Annals of Neurology. 56: 670-4. PMID 15468075 DOI: 10.1002/Ana.20248  0.403
2004 Tang TS, Tu H, Orban PC, Chan EY, Hayden MR, Bezprozvanny I. HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca release in primary culture of striatal medium spiny neurons. The European Journal of Neuroscience. 20: 1779-87. PMID 15379999 DOI: 10.1111/J.1460-9568.2004.03633.X  0.34
2004 Ross CJ, Twisk J, Meulenberg JM, Liu G, van den Oever K, Moraal E, Hermens WT, Rip J, Kastelein JJ, Kuivenhoven JA, Hayden MR. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Human Gene Therapy. 15: 906-19. PMID 15353045 DOI: 10.1089/Hum.2004.15.906  0.32
2004 Trushina E, Dyer RB, Badger JD, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS, Van Houten B, Zeitlin S, McNiven M, Aebersold R, Hayden M, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Molecular and Cellular Biology. 24: 8195-209. PMID 15340079 DOI: 10.1128/Mcb.24.18.8195-8209.2004  0.35
2004 Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochemical and Biophysical Research Communications. 322: 1310-7. PMID 15336977 DOI: 10.1016/J.Bbrc.2004.08.035  0.385
2004 Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. The Journal of Biological Chemistry. 279: 41197-207. PMID 15269218 DOI: 10.1074/Jbc.M407962200  0.307
2004 Li L, Murphy TH, Hayden MR, Raymond LA. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. Journal of Neurophysiology. 92: 2738-46. PMID 15240759 DOI: 10.1152/Jn.00308.2004  0.397
2004 Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES, Steinberg MH, Nolan V, Baldwin CT, Hotchkiss RS, Buchman TG, Zehnbauer BA, Hayden MR, Farrer LA, Roy S, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature. 429: 75-9. PMID 15129283 DOI: 10.1038/Nature02451  0.655
2004 Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, ... ... Hayden MR, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics. 74: 1064-73. PMID 15060842 DOI: 10.1086/420795  0.598
2004 Harper PS, Gevers S, de Wert G, Creighton S, Bombard Y, Hayden MR. Genetic testing and Huntington's disease: issues of employment. The Lancet. Neurology. 3: 249-52. PMID 15039038 DOI: 10.1016/S1474-4422(04)00711-2  0.337
2004 Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, Raymond LA. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Molecular and Cellular Neurosciences. 25: 469-79. PMID 15033175 DOI: 10.1016/J.Mcn.2003.11.014  0.371
2004 Djoussé L, Knowlton B, Hayden MR, Almqvist EW, Brinkman RR, Ross CA, Margolis RL, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics. 5: 109-14. PMID 15029481 DOI: 10.1007/S10048-004-0175-2  0.637
2004 Selva DM, Hirsch-Reinshagen V, Burgess B, Zhou S, Chan J, McIsaac S, Hayden MR, Hammond GL, Vogl AW, Wellington CL. The ATP-binding cassette transporter 1 mediates lipid efflux from Sertoli cells and influences male fertility. Journal of Lipid Research. 45: 1040-50. PMID 15026428 DOI: 10.1194/Jlr.M400007-Jlr200  0.317
2004 Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics. 65: 267-77. PMID 15025718 DOI: 10.1111/J.1399-0004.2004.00241.X  0.616
2004 Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. The Journal of Biological Chemistry. 279: 20211-20. PMID 14981075 DOI: 10.1074/Jbc.M401267200  0.43
2004 Hovingh GK, Kuivenhoven JA, Bisoendial RJ, Groen AK, Van Dam M, Van Tol A, Wellington C, Hayden MR, Smelt AHM, Kastelein JJP. HDL deficiency and atherosclerosis: Lessons from Tangier disease [1] Journal of Internal Medicine. 255: 299-301. PMID 14746569 DOI: 10.1046/J.0954-6820.2003.01256.X  0.348
2004 Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, Kegel KB, Aronin N, DiFiglia M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 269-81. PMID 14715959 DOI: 10.1523/Jneurosci.1409-03.2004  0.341
2004 Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, ... Hayden MR, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death and Differentiation. 11: 424-38. PMID 14713958 DOI: 10.1038/Sj.Cdd.4401358  0.396
2004 Zala D, Bensadoun JC, Pereira de Almeida L, Leavitt BR, Gutekunst CA, Aebischer P, Hayden MR, Déglon N. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Experimental Neurology. 185: 26-35. PMID 14697316 DOI: 10.1016/J.Expneurol.2003.09.002  0.406
2004 Ross CJD, Twisk J, Kuivenhoven JA, Liu G, Miao F, Oever Kvd, Beetz M, Verbart D, Bakker A, Oranje PPA, Hermens WT, Dijkhuizen P, Kastelein JJP, Meulenberg JJM, Hayden MR. 40. Correction of Dyslipidemia in Murine and Feline Models of Lipoprotein Lipase Deficiency by Intramuscular Administration of AAV1-LPLS447X Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.063  0.36
2004 Margolis RL, Holmes SE, Rosenblatt A, Gourley L, O'Hearn E, Ross CA, Seltzer WK, Walker RH, Ashizawa T, Rasmussen A, Hayden M, Almqvist EW, Harris J, Fahn S, MacDonald ME, et al. Erratum: Huntington's disease-like 2 (HDL2) in North America and Japan (Annals of Neurology (November 2004) 56 (670-674)) Annals of Neurology. 56. DOI: 10.1002/Ana.20349  0.338
2003 Squitieri F, Almqvist EW, Cannella M, Cislaghi G, Hayden MR. Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene. Clinical Genetics. 64: 524-525. PMID 14986835 DOI: 10.1046/J.1399-0004.2003.00155.X  0.307
2003 Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, Murphy TH, Raymond LA. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiology of Aging. 24: 1113-21. PMID 14643383 DOI: 10.1016/J.Neurobiolaging.2003.04.003  0.399
2003 Almqvist EW, Brinkman RR, Wiggins S, Hayden MR. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clinical Genetics. 64: 300-9. PMID 12974735 DOI: 10.1034/J.1399-0004.2003.00157.X  0.53
2003 Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, Leavitt BR, Cattaneo E, Ferrante RJ, Hayden MR, Friedlander RM. Depletion of wild-type huntingtin in mouse models of neurologic diseases. Journal of Neurochemistry. 87: 101-6. PMID 12969257 DOI: 10.1046/J.1471-4159.2003.01980.X  0.449
2003 Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dodé C, Morrison PJ, Suchowersky O, Ross CA, Margolis RL, Rosenblatt A, Gómez-Tortosa E, Cabrero DM, Novelletto A, Frontali M, et al. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. American Journal of Human Genetics. 73: 682-7. PMID 12900792 DOI: 10.1086/378133  0.617
2003 Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, Cataudella T, Leavitt BR, Hayden MR, Timmusk T, Rigamonti D, Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics. 35: 76-83. PMID 12881722 DOI: 10.1038/Ng1219  0.389
2003 Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron. 39: 227-39. PMID 12873381 DOI: 10.1016/S0896-6273(03)00366-0  0.33
2003 Metzler M, Li B, Gan L, Georgiou J, Gutekunst CA, Wang Y, Torre E, Devon RS, Oh R, Legendre-Guillemin V, Rich M, Alvarez C, Gertsenstein M, McPherson PS, Nagy A, ... ... Hayden MR, et al. Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking. The Embo Journal. 22: 3254-66. PMID 12839988 DOI: 10.1093/Emboj/Cdg334  0.352
2003 Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Molecular Genetics. 12: 1555-67. PMID 12812983 DOI: 10.1093/Hmg/Ddg169  0.825
2003 Creighton S, Almqvist EW, MacGregor D, Fernandez B, Hogg H, Beis J, Welch JP, Riddell C, Lokkesmoe R, Khalifa M, MacKenzie J, Sajoo A, Farrell S, Robert F, Shugar A, ... ... Hayden MR, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clinical Genetics. 63: 462-75. PMID 12786753 DOI: 10.1034/J.1399-0004.2003.00093.X  0.323
2003 Djoussé L, Knowlton B, Hayden M, Almqvist EW, Brinkman R, Ross C, Margolis R, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, et al. Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. American Journal of Medical Genetics. Part A. 119: 279-82. PMID 12784292 DOI: 10.1002/Ajmg.A.20190  0.633
2003 Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR. Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arteriosclerosis, Thrombosis, and Vascular Biology. 23: 1322-32. PMID 12763760 DOI: 10.1161/01.Atv.0000078520.89539.77  0.363
2003 Wellington CL, Brunham LR, Zhou S, Singaraja RR, Visscher H, Gelfer A, Ross C, James E, Liu G, Huber MT, Yang YZ, Parks RJ, Groen A, Fruchart-Najib J, Hayden MR. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. Journal of Lipid Research. 44: 1470-80. PMID 12730295 DOI: 10.1194/Jlr.M300110-Jlr200  0.32
2003 Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi AC, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato SD. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain : a Journal of Neurology. 126: 946-55. PMID 12615650 DOI: 10.1093/Brain/Awg077  0.41
2003 Nucifora FC, Ellerby LM, Wellington CL, Wood JD, Herring WJ, Sawa A, Hayden MR, Dawson VL, Dawson TM, Ross CA. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. The Journal of Biological Chemistry. 278: 13047-55. PMID 12464607 DOI: 10.1074/Jbc.M211224200  0.361
2003 Singaraja R, Visscher H, James E, Hayden M. 2P-0445 Biochemical characterization of mutations in ABCA1 correlate with disease severity Atherosclerosis Supplements. 4: 137. DOI: 10.1016/S1567-5688(03)90587-3  0.324
2003 Wellington CL, Ellerby LM, Leavitt BR, Roy S, Nicholson DW, Hayden MR. Huntington proteolysis in Huntington disease Clinical Neuroscience Research. 3: 129-139. DOI: 10.1016/S1566-2772(03)00055-0  0.453
2002 Wellington CL, Yang YZ, Zhou S, Clee SM, Tan B, Hirano K, Zwarts K, Kwok A, Gelfer A, Marcil M, Newman S, Roomp K, Singaraja R, Collins J, Zhang LH, ... ... Hayden MR, et al. Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. Journal of Lipid Research. 43: 1939-49. PMID 12401893 DOI: 10.1194/Jlr.M200277-Jlr200  0.674
2002 Singaraja RR, Hadano S, Metzler M, Givan S, Wellington CL, Warby S, Yanai A, Gutekunst CA, Leavitt BR, Yi H, Fichter K, Gan L, McCutcheon K, Chopra V, Michel J, ... ... Hayden MR, et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Human Molecular Genetics. 11: 2815-28. PMID 12393793 DOI: 10.1093/Hmg/11.23.2815  0.38
2002 Attie AD, Hamon Y, Brooks-Wilson AR, Gray-Keller MP, MacDonald ML, Rigot V, Tebon A, Zhang LH, Mulligan JD, Singaraja RR, Bitgood JJ, Cook ME, Kastelein JJ, Chimini G, Hayden MR. Identification and functional analysis of a naturally occurring E89K mutation in the ABCA1 gene of the WHAM chicken. Journal of Lipid Research. 43: 1610-7. PMID 12364545 DOI: 10.1194/Jlr.M200223-Jlr200  0.365
2002 Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, Hersch SM, Leavitt BR, Roy S, ... ... Hayden MR, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 7862-72. PMID 12223539 DOI: 10.1523/Jneurosci.22-18-07862.2002  0.8
2002 Robitaille J, MacDonald ML, Kaykas A, Sheldahl LC, Zeisler J, Dubé MP, Zhang LH, Singaraja RR, Guernsey DL, Zheng B, Siebert LF, Hoskin-Mott A, Trese MT, Pimstone SN, Shastry BS, ... ... Hayden MR, et al. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nature Genetics. 32: 326-30. PMID 12172548 DOI: 10.1038/Ng957  0.324
2002 Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Human Molecular Genetics. 11: 1939-51. PMID 12165556 DOI: 10.1093/Hmg/11.17.1939  0.426
2002 Ariano MA, Aronin N, Difiglia M, Tagle DA, Sibley DR, Leavitt BR, Hayden MR, Levine MS. Striatal neurochemical changes in transgenic models of Huntington's disease. Journal of Neuroscience Research. 68: 716-29. PMID 12111832 DOI: 10.1002/Jnr.10272  0.349
2002 Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart JC, McManus BM, Staels B, Hayden MR. Increased ABCA1 activity protects against atherosclerosis. The Journal of Clinical Investigation. 110: 35-42. PMID 12093886 DOI: 10.1172/Jci15748  0.674
2002 Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience. 5: 731-6. PMID 12089530 DOI: 10.1038/Nn884  0.367
2002 Bu L, Jin Y, Shi Y, Chu R, Ban A, Eiberg H, Andres L, Jiang H, Zheng G, Qian M, Cui B, Xia Y, Liu J, Hu L, Zhao G, ... Hayden MR, et al. Mutant DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner cataract. Nature Genetics. 31: 276-8. PMID 12089525 DOI: 10.1038/Ng921  0.306
2002 Chan EY, Nasir J, Gutekunst CA, Coleman S, Maclean A, Maas A, Metzler M, Gertsenstein M, Ross CA, Nagy A, Hayden MR. Targeted disruption of Huntingtin-associated protein-1 (Hap1) results in postnatal death due to depressed feeding behavior. Human Molecular Genetics. 11: 945-59. PMID 11971876 DOI: 10.1093/Hmg/11.8.945  0.331
2002 Zwarts KY, Clee SM, Zwinderman AH, Engert JC, Singaraja R, Loubser O, James E, Roomp K, Hudson TJ, Jukema JW, Kastelein JJ, Hayden MR. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clinical Genetics. 61: 115-25. PMID 11940086 DOI: 10.1034/J.1399-0004.2002.610206.X  0.667
2002 Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 33: 849-60. PMID 11906693 DOI: 10.1016/S0896-6273(02)00615-3  0.378
2002 Wellington CL, Walker EK, Suarez A, Kwok A, Bissada N, Singaraja R, Yang YZ, Zhang LH, James E, Wilson JE, Francone O, McManus BM, Hayden MR. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Laboratory Investigation; a Journal of Technical Methods and Pathology. 82: 273-83. PMID 11896206 DOI: 10.1038/Labinvest.3780421  0.308
2002 van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, Zwinderman AH, Smit AJ, Smelt AH, Groen AK, Hayden MR, Kastelein JJ. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet (London, England). 359: 37-42. PMID 11809185 DOI: 10.1016/S0140-6736(02)07277-X  0.657
2002 Gervais FG, Singaraja R, Xanthoudakis S, Gutekunst CA, Leavitt BR, Metzler M, Hackam AS, Tam J, Vaillancourt JP, Houtzager V, Rasper DM, Roy S, Hayden MR, Nicholson DW. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nature Cell Biology. 4: 95-105. PMID 11788820 DOI: 10.1038/Ncb735  0.362
2002 Nishida Y, Hirano KI, Tsukamoto K, Nagano M, Ikegami C, Roomp K, Ishihara M, Sakane N, Zhang Z, Tsujii KI, Matsuyama A, Ohama T, Matsuura F, Ishigami M, Sakai N, ... ... Hayden MR, et al. Expression and functional analyses of novel mutations of ATP-binding cassette transporter-1 in Japanese patients with high-density lipoprotein deficiency Biochemical and Biophysical Research Communications. 290: 713-721. PMID 11785958 DOI: 10.1006/Bbrc.2001.6219  0.332
2002 Squitieri F, Cannella M, Giallonardo P, Maglione V, Mariotti C, Hayden MR. Onset and pre-onset studies to define the Huntington's disease natural history. Brain Research Bulletin. 56: 233-8. PMID 11719256 DOI: 10.1016/S0361-9230(01)00648-7  0.388
2001 Cepeda C, Ariano MA, Calvert CR, Flores-Hernández J, Chandler SH, Leavitt BR, Hayden MR, Levine MS. NMDA receptor function in mouse models of Huntington disease. Journal of Neuroscience Research. 66: 525-39. PMID 11746372 DOI: 10.1002/Jnr.1244  0.357
2001 Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clinical Genetics. 60: 293-300. PMID 11683775 DOI: 10.1034/J.1399-0004.2001.600407.X  0.653
2001 Almqvist EW, Elterman DS, MacLeod PM, Hayden MR. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia Clinical Genetics. 60: 198-205. PMID 11595021 DOI: 10.1034/J.1399-0004.2001.600305.X  0.351
2001 Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, Figlewicz DA, Kwiatkowski T, Hosler BA, Sagie T, Skaug J, ... ... Hayden MR, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nature Genetics. 29: 166-73. PMID 11586298 DOI: 10.1038/Ng1001-166  0.337
2001 Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 57: 658-62. PMID 11524475 DOI: 10.1212/Wnl.57.4.658  0.627
2001 Metzler M, Legendre-Guillemin V, Gan L, Chopra V, Kwok A, McPherson PS, Hayden MR. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. The Journal of Biological Chemistry. 276: 39271-6. PMID 11517213 DOI: 10.1074/Jbc.C100401200  0.324
2001 Peel AL, Rao RV, Cottrell BA, Hayden MR, Ellerby LM, Bredesen DE. Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Human Molecular Genetics. 10: 1531-8. PMID 11468270 DOI: 10.1093/Hmg/10.15.1531  0.371
2001 Rosenblatt A, Brinkman RR, Liang KY, Almqvist EW, Margolis RL, Huang CY, Sherr M, Franz ML, Abbott MH, Hayden MR, Ross CA. Familial influence on age of onset among siblings with Huntington disease. American Journal of Medical Genetics. 105: 399-403. PMID 11449389 DOI: 10.1002/Ajmg.1400  0.591
2001 Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, Tan B, Brooks-Wilson A, Kwok A, Bissada N, Yang YZ, Liu G, Tafuri SR, Fievet C, Wellington CL, ... ... Hayden MR, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. The Journal of Biological Chemistry. 276: 33969-79. PMID 11423537 DOI: 10.1074/Jbc.M102503200  0.688
2001 Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (New York, N.Y.). 293: 493-8. PMID 11408619 DOI: 10.1126/Science.1059581  0.39
2001 McGladdery SH, Pimstone SN, Clee SM, Bowden JF, Hayden MR, Frohlich JJ. Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. Atherosclerosis. 156: 401-7. PMID 11395037 DOI: 10.1016/S0021-9150(00)00670-5  0.655
2001 Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, Jukema JW, van Wijland M, van Dam M, Hudson TJ, Brooks-Wilson A, Genest J, Kastelein JJ, Hayden MR. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation. 103: 1198-205. PMID 11238261 DOI: 10.1161/01.Cir.103.9.1198  0.672
2001 Falush D, Almqvist EW, Brinkmann RR, Iwasa Y, Hayden MR. Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. American Journal of Human Genetics. 68: 373-85. PMID 11225602 DOI: 10.1086/318193  0.347
2001 Backus RC, Ginzinger DG, Ashbourne Excoffon KJ, Clee SM, Hayden MR, Eckel RH, Hickman MA, Rogers QR. Maternal expression of functional lipoprotein lipase and effects on body fat mass and body condition scores of mature cats with lipoprotein lipase deficiency. American Journal of Veterinary Research. 62: 264-9. PMID 11212037 DOI: 10.2460/Ajvr.2001.62.264  0.627
2001 Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, Margolis RL, Ross CA, Dausset J, Ferrante RJ, Néri C. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 98: 1811-6. PMID 11172033 DOI: 10.1073/Pnas.98.4.1811  0.36
2001 Hadano S, Yanagisawa Y, Skaug J, Fichter K, Nasir J, Martindale D, Koop BF, Scherer SW, Nicholson DW, Rouleau GA, Ikeda J, Hayden MR. Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2. Genomics. 71: 200-13. PMID 11161814 DOI: 10.1006/Geno.2000.6392  0.343
2001 Zeron MM, Chen N, Moshaver A, Lee AT, Wellington CL, Hayden MR, Raymond LA. Mutant huntingtin enhances excitotoxic cell death. Molecular and Cellular Neurosciences. 17: 41-53. PMID 11161468 DOI: 10.1006/Mcne.2000.0909  0.345
2001 Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. American Journal of Human Genetics. 68: 313-24. PMID 11133364 DOI: 10.1086/318207  0.424
2000 Wellington CL, Leavitt BR, Hayden MR. Huntington disease: new insights on the role of huntingtin cleavage. Journal of Neural Transmission. Supplementum. 1-17. PMID 11128600 DOI: 10.1007/978-3-7091-6284-2_1  0.427
2000 Tsuang D, Almqvist EW, Lipe H, Strgar F, DiGiacomo L, Hoff D, Eugenio C, Hayden MR, Bird TD. Familial aggregation of psychotic symptoms in Huntington's disease. The American Journal of Psychiatry. 157: 1955-9. PMID 11097960 DOI: 10.1176/Appi.Ajp.157.12.1955  0.346
2000 Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY, Collins JA, Roelants R, Tamasawa N, Stulc T, Suda T, Ceska R, Boucher B, Rondeau C, DeSouich C, ... ... Hayden MR, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. The Journal of Clinical Investigation. 106: 1263-70. PMID 11086027 DOI: 10.1172/Jci10727  0.673
2000 Hackam AS, Yassa AS, Singaraja R, Metzler M, Gutekunst CA, Gan L, Warby S, Wellington CL, Vaillancourt J, Chen N, Gervais FG, Raymond L, Nicholson DW, Hayden MR. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. The Journal of Biological Chemistry. 275: 41299-308. PMID 11007801 DOI: 10.1074/Jbc.M008408200  0.327
2000 Nasir J, Lafuente MJ, Duan K, Colomer V, Engelender S, Ingersoll R, Margolis RL, Ross CA, Hayden MR. Human huntingtin-associated protein (HAP-1) gene: genomic organisation and an intragenic polymorphism. Gene. 254: 181-7. PMID 10974549 DOI: 10.1016/S0378-1119(00)00269-9  0.33
2000 Clarke G, Collins RA, Leavitt BR, Andrews DF, Hayden MR, Lumsden CJ, McInnes RR. A one-hit model of cell death in inherited neuronal degenerations. Nature. 406: 195-9. PMID 10910361 DOI: 10.1038/35018098  0.353
2000 Hayden MR, Clee SM, Brooks-Wilson A, Genest J, Attie A, Kastelein JJ. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Current Opinion in Lipidology. 11: 117-22. PMID 10787172 DOI: 10.1097/00041433-200004000-00003  0.657
2000 Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson DW, Bredesen DE, Hayden MR. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. The Journal of Biological Chemistry. 275: 19831-8. PMID 10770929 DOI: 10.1074/Jbc.M001475200  0.371
2000 Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, Steures P, McManus J, McManus B, LeBoeuf RC, Kastelein JJ, Hayden MR. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. Journal of Lipid Research. 41: 521-31. PMID 10744772  0.646
2000 Wellington CL, Hayden MR. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clinical Genetics. 57: 1-10. PMID 10733228 DOI: 10.1034/J.1399-0004.2000.570101.X  0.364
2000 Metzler M, Helgason CD, Dragatsis I, Zhang T, Gan L, Pineault N, Zeitlin SO, Humphries RK, Hayden MR. Huntingtin is required for normal hematopoiesis. Human Molecular Genetics. 9: 387-94. PMID 10655548 DOI: 10.1093/Hmg/9.3.387  0.384
2000 Liu G, Ashbourne Excoffon KJ, Wilson JE, McManus BM, Rogers QR, Miao L, Kastelein JJ, Lewis ME, Hayden MR. Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Human Gene Therapy. 11: 21-32. PMID 10646636 DOI: 10.1089/10430340050016120  0.317
2000 Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E. Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3 The Journal of Neuroscience. 20: 3705-3713. DOI: 10.1523/Jneurosci.20-10-03705.2000  0.382
1999 Leavitt BR, Wellington CL, Hayden MR. Recent insights into the molecular pathogenesis of Huntington disease. Seminars in Neurology. 19: 385-95. PMID 10716661 DOI: 10.1055/S-2008-1040853  0.442
1999 Wittekoek ME, Moll E, Pimstone SN, Trip MD, Lansberg PJ, Defesche JC, van Doormaal JJ, Hayden MR, Kastelein JJ. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 19: 2708-13. PMID 10559015 DOI: 10.1161/01.Atv.19.11.2708  0.32
1999 Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, Collins JA, van Dam M, Molhuizen HO, Loubster O, Ouellette BF, Sensen CW, Fichter K, Mott S, Denis M, ... ... Hayden MR, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 354: 1341-6. PMID 10533863 DOI: 10.1016/S0140-6736(99)07026-9  0.671
1999 Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, Mezei M, Hardy MA, Snow B, Martin W, Hayden MR. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology. 53: 1000-11. PMID 10496259 DOI: 10.1212/Wnl.53.5.1000  0.351
1999 Hackam AS, Hodgson JG, Singaraja R, Zhang T, Gan L, Gutekunst CA, Hersch SM, Hayden MR. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 1047-55. PMID 10434304 DOI: 10.1098/Rstb.1999.0457  0.401
1999 Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, ... ... Hayden MR, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genetics. 22: 336-45. PMID 10431236 DOI: 10.1038/11905  0.683
1999 Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, ... ... Hayden MR, et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23: 181-92. PMID 10402204 DOI: 10.1016/S0896-6273(00)80764-3  0.441
1999 Kim M, Velier J, Chase K, Laforet G, Kalchman MA, Hayden MR, Won L, Heller A, Aronin N, Difiglia M. Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin. Neuroscience. 89: 1159-67. PMID 10362304 DOI: 10.1016/S0306-4522(98)00400-X  0.303
1999 Bruland O, Almqvist EW, Goldberg YP, Boman H, Hayden MR, Knappskog PM. Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequence-specific internal DNA standard. Clinical Genetics. 55: 198-202. PMID 10334474 DOI: 10.1034/J.1399-0004.1999.550308.X  0.3
1999 Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, Raymond LA. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. Journal of Neurochemistry. 72: 1890-8. PMID 10217265 DOI: 10.1046/J.1471-4159.1999.0721890.X  0.311
1999 Almqvist EW, Bloch M, Brinkman R, Craufurd D, Hayden MR. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. American Journal of Human Genetics. 64: 1293-304. PMID 10205260 DOI: 10.1086/302374  0.554
1999 Ginzinger DG, Clee SM, Dallongeville J, Lewis ME, Henderson HE, Bauje E, Rogers QR, Jensen DR, Eckel RH, Dyer R, Innis S, Jones B, Fruchart JC, Hayden MR. Lipid and lipoprotein analysis of cats with lipoprotein lipase deficiency. European Journal of Clinical Investigation. 29: 17-26. PMID 10092984 DOI: 10.1046/j.1365-2362.1999.00435.x  0.628
1999 Ellerby LM, Andrusiak RL, Wellington CL, Hackam AS, Propp SS, Wood JD, Sharp AH, Margolis RL, Ross CA, Salvesen GS, Hayden MR, Bredesen DE. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. The Journal of Biological Chemistry. 274: 8730-6. PMID 10085113 DOI: 10.1074/Jbc.274.13.8730  0.359
1999 O'Kusky JR, Nasir J, Cicchetti F, Parent A, Hayden MR. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. Brain Research. 818: 468-79. PMID 10082833 DOI: 10.1016/S0006-8993(98)01312-2  0.423
1999 Metzler M, Chen N, Helgason CD, Graham RK, Nichol K, McCutcheon K, Nasir J, Humphries RK, Raymond LA, Hayden MR. Life without huntingtin: normal differentiation into functional neurons. Journal of Neurochemistry. 72: 1009-18. PMID 10037472 DOI: 10.1046/J.1471-4159.1999.0721009.X  0.67
1999 Hadano S, Nichol K, Brinkman RR, Nasir J, Martindale D, Koop BF, Nicholson DW, Scherer SW, Ikeda JE, Hayden MR. A yeast artificial chromosome-based physical map of the juvenile amyotrophic lateral sclerosis (ALS2) critical region on human chromosome 2q33-q34. Genomics. 55: 106-12. PMID 9889004 DOI: 10.1006/Geno.1998.5637  0.554
1999 Hackam AS, Singaraja R, Zhang T, Gan L, Hayden MR. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Human Molecular Genetics. 8: 25-33. PMID 9887328 DOI: 10.1093/Hmg/8.1.25  0.363
1999 Ellerby LM, Hackam AS, Propp SS, Ellerby HM, Rabizadeh S, Cashman NR, Trifiro MA, Pinsky L, Wellington CL, Salvesen GS, Hayden MR, Bredesen DE. Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. Journal of Neurochemistry. 72: 185-95. PMID 9886069 DOI: 10.1046/J.1471-4159.1999.0720185.X  0.381
1998 Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, MacPherson DP, ... ... Hayden MR, et al. Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death and Differentiation. 5: 271-88. PMID 10200473 DOI: 10.1038/Sj.Cdd.4400370  0.312
1998 Xiang F, Almqvist EW, Huq M, Lundin A, Hayden MR, Edström L, Anvret M, Zhang Z. A Huntington disease-like neurodegenerative disorder maps to chromosome 20p. American Journal of Human Genetics. 63: 1431-8. PMID 9792871 DOI: 10.1086/302093  0.359
1998 Nasir J, Duan K, Nichol K, Engelender S, Ashworth R, Colomer V, Thomas S, Disteche CM, Hayden MR, Ross CA. Gene structure and map location of the murine homolog of the Huntington-associated protein, Hap1. Mammalian Genome : Official Journal of the International Mammalian Genome Society. 9: 565-70. PMID 9657855 DOI: 10.1007/S003359900819  0.356
1998 Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T, Kalchman M, Hayden MR. The influence of huntingtin protein size on nuclear localization and cellular toxicity. The Journal of Cell Biology. 141: 1097-105. PMID 9606203 DOI: 10.1083/Jcb.141.5.1097  0.344
1998 Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, Rowland KJ, Zhang T, Rasper D, Roy S, Thornberry N, ... ... Hayden MR, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. The Journal of Biological Chemistry. 273: 9158-67. PMID 9535906 DOI: 10.1074/Jbc.273.15.9158  0.379
1998 Wittekoek ME, Pimstone SN, Reymer PW, Feuth L, Botma GJ, Defesche JC, Prins M, Hayden MR, Kastelein JJ. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation. 97: 729-35. PMID 9498535 DOI: 10.1161/01.Cir.97.8.729  0.336
1998 Henderson H, Leisegang F, Hassan F, Hayden M, Marais D. A novel Glu421Lys substitution in the lipoprotein lipase gene in pregnancy-induced hypertriglyceridemic pancreatitis. Clinica Chimica Acta; International Journal of Clinical Chemistry. 269: 1-12. PMID 9498099 DOI: 10.1016/S0009-8981(97)00144-7  0.309
1998 Pimstone SN, Sun XM, du Souich C, Frohlich JJ, Hayden MR, Soutar AK. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arteriosclerosis, Thrombosis, and Vascular Biology. 18: 309-15. PMID 9484998 DOI: 10.1161/01.Atv.18.2.309  0.318
1998 Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja R, Kazemi-Esfarjani P, Devon R, Kim SU, Bredesen DE, Tufaro F, Hayden MR. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates Nature Genetics. 18: 150-154. PMID 9462744 DOI: 10.1038/Ng0298-150  0.365
1997 Ehrenborg E, Clee SM, Pimstone SN, Reymer PW, Benlian P, Hoogendijk CF, Davis HJ, Bissada N, Miao L, Gagné SE, Greenberg LJ, Henry R, Henderson H, Ordovas JM, Schaefer EJ, ... ... Hayden MR, et al. Ethnic variation and in vivo effects of the -93t-->g promoter variant in the lipoprotein lipase gene. Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 2672-8. PMID 9409241 DOI: 10.1161/01.Atv.17.11.2672  0.651
1997 Excoffon KJ, Liu G, Miao L, Wilson JE, McManus BM, Semenkovich CF, Coleman T, Benoit P, Duverger N, Branellec D, Denefle P, Hayden MR, Lewis ME. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 2532-9. PMID 9409224 DOI: 10.1161/01.Atv.17.11.2532  0.354
1997 Ginzinger DG, Wilson JE, Redenbach D, Lewis ME, Clee SM, Excoffon KJ, Rogers QR, Hayden MR, McManus BM. Diet-induced atherosclerosis in the domestic cat. Laboratory Investigation; a Journal of Technical Methods and Pathology. 77: 409-19. PMID 9389784  0.61
1997 Almqvist E, Adam S, Bloch M, Fuller A, Welch P, Eisenberg D, Whelan D, Macgregor D, Meschino W, Hayden MR. Risk reversals in predictive testing for Huntington disease. American Journal of Human Genetics. 61: 945-52. PMID 9382108 DOI: 10.1086/514873  0.304
1997 Clee SM, Zhang H, Bissada N, Miao L, Ehrenborg E, Benlian P, Shen GX, Angel A, LeBoeuf RC, Hayden MR. Relationship between lipoprotein lipase and high density lipoprotein cholesterol in mice: modulation by cholesteryl ester transfer protein and dietary status. Journal of Lipid Research. 38: 2079-89. PMID 9374130  0.647
1997 Andrew SE, Goldberg YP, Hayden MR. Rethinking genotype and phenotype correlations in polyglutamine expansion disorders Human Molecular Genetics. 6: 2005-2010. PMID 9328463 DOI: 10.1093/Hmg/6.12.2005  0.392
1997 Foubert L, Bruin T, De Gennes JL, Ehrenborg E, Furioli J, Kastelein J, Benlian P, Hayden M. A single Ser259Arg mutation in the gene for lipoprotein lipase causes chylomicronemia in Moroccans of Berber ancestry. Human Mutation. 10: 179-85. PMID 9298816 DOI: 10.1002/(Sici)1098-1004(1997)10:3<179::Aid-Humu1>3.0.Co;2-E  0.317
1997 Wellington CL, Hayden MR. Of molecular interactions, mice and mechanisms: New insights into Huntington's disease Current Opinion in Neurology. 10: 291-298. PMID 9266152 DOI: 10.1097/00019052-199708000-00003  0.413
1997 Wellington CL, Brinkman RR, O'Kusky JR, Hayden MR. Toward understanding the molecular pathology of Huntington's disease. Brain Pathology (Zurich, Switzerland). 7: 979-1002. PMID 9217979 DOI: 10.1111/J.1750-3639.1997.Tb00897.X  0.661
1997 Groenemeijer BE, Hallman MD, Reymer PW, Gagné E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Circulation. 95: 2628-35. PMID 9193431 DOI: 10.1161/01.Cir.95.12.2628  0.313
1997 Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJ. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 826-33. PMID 9157944 DOI: 10.1161/01.Atv.17.5.826  0.656
1997 Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. American Journal of Human Genetics. 60: 1202-10. PMID 9150168  0.546
1997 Kalchman MA, Koide HB, McCutcheon K, Graham RK, Nichol K, Nishiyama K, Kazemi-Esfarjani P, Lynn FC, Wellington C, Metzler M, Goldberg YP, Kanazawa I, Gietz RD, Hayden MR. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nature Genetics. 16: 44-53. PMID 9140394 DOI: 10.1038/ng0597-44  0.646
1997 Chong SS, Almqvist E, Telenius H, LaTray L, Nichol K, Bourdelat-Parks B, Goldberg YP, Haddad BR, Richards F, Sillence D, Greenberg CR, Ives E, Van Den Engh G, Hughes MR, Hayden MR. Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: Evidence from single sperm analyses Human Molecular Genetics. 6: 301-309. PMID 9063751 DOI: 10.1093/Hmg/6.2.301  0.322
1997 Liu G, Excoffon KJ, Benoit P, Ginzinger DG, Miao L, Ehrenborg E, Duverger N, Denefle PP, Hayden MR, Lewis ME. Efficient adenovirus-mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cells. Human Gene Therapy. 8: 205-14. PMID 9017424 DOI: 10.1089/Hum.1997.8.2-205  0.316
1997 Bijvoet SM, Wiebusch H, Ma Y, Reymer PW, Bruin T, Bakker HD, Funke H, Assmann G, Hayden MR, Kastelein JJ. Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250-->Asn; Ser251-->Cys) resulting in lipoprotein lipase (LPL) deficiency. The Netherlands Journal of Medicine. 49: 189-95. PMID 8973094 DOI: 10.1016/0300-2977(96)00043-5  0.307
1996 Hodgson JG, Smith DJ, McCutcheon K, Koide HB, Nishiyama K, Dinulos MB, Stevens ME, Bissada N, Nasir J, Kanazawa I, Disteche CM, Rubin EM, Hayden MR. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype Human Molecular Genetics. 5: 1875-1885. PMID 8968738 DOI: 10.1093/Hmg/5.12.1875  0.413
1996 Nasir J, Goldberg YP, Hayden MR. Huntington disease: New insights into the relationship between CAG expansion and disease Human Molecular Genetics. 5: 1431-1435. PMID 8875248 DOI: 10.1093/Hmg/5.Supplement_1.1431  0.45
1996 Pimstone SN, Clee SM, Gagné SE, Miao L, Zhang H, Stein EA, Hayden MR. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. Journal of Lipid Research. 37: 1675-84. PMID 8864951  0.64
1996 Squitieri F, Campanella G, Hayden MR. Update on genetics of Huntington's disease: availability of direct and accurate predictive test Italian Journal of Neurological Sciences. 17: 185-187. PMID 8856407 DOI: 10.1007/Bf01995681  0.301
1996 Goldberg YP, Kalchman MA, Metzler M, Nasir J, Zeisler J, Graham R, Koide HB, O'Kusky J, Sharp AH, Ross CA, Jirik F, Hayden MR. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript Human Molecular Genetics. 5: 177-185. PMID 8824873 DOI: 10.1093/Hmg/5.2.177  0.727
1996 Burgess MM, Hayden MR. Patients' rights to laboratory data: Trinucleotide repeat length in huntington disease American Journal of Medical Genetics. 62: 6-9. PMID 8779327 DOI: 10.1002/(Sici)1096-8628(19960301)62:1<6::Aid-Ajmg2>3.0.Co;2-X  0.312
1996 Kalchman MA, Graham RK, Xia G, Brook Koide H, Graeme Hodgson J, Graham KC, Paul Goldberg Y, Dan Gietz R, Pickart CM, Hayden MR. Huntingtin is ubiquitinated and interacts with a specific ubiquitin- conjugating enzyme Journal of Biological Chemistry. 271: 19385-19394. PMID 8702625 DOI: 10.1074/Jbc.271.32.19385  0.647
1996 Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, Hayden MR. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genetics. 13: 442-9. PMID 8696339 DOI: 10.1038/Ng0896-442  0.675
1996 Zhang H, Henderson H, Gagne SE, Clee SM, Miao L, Liu G, Hayden MR. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochimica Et Biophysica Acta. 1302: 159-66. PMID 8695666 DOI: 10.1016/0005-2760(96)00059-8  0.674
1996 Goldberg YP, McMurray CT, Zeisler J, Almqvist E, Sillence D, Richards F, Gacy AM, Buchanan J, Telenius H, Hayden MR. Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Human Molecular Genetics. 4: 1911-8. PMID 8595415 DOI: 10.1093/Hmg/4.10.1911  0.349
1996 Suzanne Lewis M, Liu G, Ginzinger DG, Benoit P, Jones SD, Ashbourne KJ, Wilson JE, McManus BM, Duverger N, Denefle PP, Hayden MR. Gene-based therapeutic strategies for Human Lipoprotein Lipase (LPL) deficiency: Rationale and prospects for alteration of atherogenic risk Transfusion Science. 17: 79-87. DOI: 10.1016/0955-3886(95)00061-5  0.347
1995 Andrew SE, Hayden MR. Origins and evolution of huntington disease chromosomes Neurodegeneration. 4: 239-244. PMID 8581556 DOI: 10.1016/1055-8330(95)90013-6  0.367
1995 Britton JW, Uitti RJ, Ahlskog JE, Robinson RG, Kremer B, Hayden MR. Hereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington's disease. Neurology. 45: 443-7. PMID 7898693 DOI: 10.1212/Wnl.45.3.443  0.326
1995 Tuzgöl S, Bijvoet SM, Bruin T, Kastelein JJ, Hayden MR. Apolipoprotein CII-Padova (Tyr37-->stop) as a cause of chylomicronaemia in an Italian kindred from Siculiana. Journal of Medical Genetics. 31: 622-6. PMID 7815420 DOI: 10.1136/Jmg.31.8.622  0.339
1995 Lin B, Nasir J, McDonald H, Graham R, Rommens JM, Goldberg YP, Hayden MR. Genomic organization of the human alpha-adducin gene and its alternately spliced isoforms. Genomics. 25: 93-9. PMID 7774961 DOI: 10.1016/0888-7543(95)80113-Z  0.628
1995 Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 81: 811-23. PMID 7774020 DOI: 10.1016/0092-8674(95)90542-1  0.466
1995 Lin B, Nasir J, Kalchman MA, McDonald H, Zeisler J, Goldberg YP, Hayden MR. Structural analysis of the 5' region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. Genomics. 25: 707-15. PMID 7759106 DOI: 10.1016/0888-7543(95)80014-D  0.343
1995 Almqvist E, Spence N, Nichol K, Andrew SE, Vesa J, Peltonen L, Anvret M, Goto J, Kanazawa I, Goldberg YP, Hayden MR. Ancestral differences in the distribution of the Δ2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease Human Molecular Genetics. 4: 207-214. PMID 7757069 DOI: 10.1093/Hmg/4.2.207  0.338
1995 Zhang H, Reymer PW, Liu MS, Forsythe IJ, Groenemeyer BE, Frohlich J, Brunzell JD, Kastelein JJ, Hayden MR, Ma Y. Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291-->Ser mutation in the human LPL gene. Arteriosclerosis, Thrombosis, and Vascular Biology. 15: 1695-703. PMID 7583546 DOI: 10.1161/01.Atv.15.10.1695  0.362
1995 Lewis MES, Forsythe IJ, Marth JD, Brunzell JD, Hayden MR, Humphries RK. Retroviral-mediated gene transfer and expression of human lipoprotein lipase in somatic cells Human Gene Therapy. 6: 853-863. PMID 7578404 DOI: 10.1089/Hum.1995.6.7-853  0.334
1994 Riess O, Thies U, Siedlaczck I, Potisek S, Graham R, Theilmann J, Grimm T, Epplen JT, Hayden MR. Precise mapping of the brain alpha 2-adrenergic receptor gene within chromosome 4p16. Genomics. 19: 298-302. PMID 8188260 DOI: 10.1006/Geno.1994.1061  0.664
1994 Lin B, Nasir J, MacDonald H, Hutchinson G, Graham RK, Rommens JM, Hayden MR. Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat [corrected]. Human Molecular Genetics. 3: 85-92. PMID 8162057 DOI: 10.1093/Hmg/3.1.85  0.688
1994 Kremer B, Squitieri F, Telenius H, Andrew SE, Theilmann J, Spence N, Goldberg YP, Hayden MR. Molecular analysis of late onset Huntington's disease. Journal of Medical Genetics. 30: 991-5. PMID 8133510 DOI: 10.1136/Jmg.30.12.991  0.319
1994 Goldberg YP, Andrew SE, Theilmann J, Kremer B, Squitieri F, Telenius H, Brown JD, Hayden MR. Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases. Journal of Medical Genetics. 30: 987-90. PMID 8133509 DOI: 10.1136/Jmg.30.12.987  0.38
1994 Bijvoet SM, Bruin T, Tuzgöl S, Bakker HD, Hayden MR, Kastelein JJ. Homozygosity for a mutation in the lipoprotein lipase gene (Gly139-->Ser) causes chylomicronaemia in a boy of Spanish descent. Human Genetics. 93: 339-43. PMID 8125488 DOI: 10.1007/Bf00212035  0.323
1994 Gagné E, Genest J, Zhang H, Clarke LA, Hayden MR. Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia Arteriosclerosis, Thrombosis, and Vascular Biology. 14: 1250-1257. PMID 8049185 DOI: 10.1161/01.Atv.14.8.1250  0.327
1994 Almqvist E, Andrew S, Theilmann J, Goldberg P, Zeisler J, Drugge U, Grandell U, Tapper-Persson M, Winblad B, Hayden M, Anvret M. Geographical distribution of haplotypes in Swedish families with Huntington's disease. Human Genetics. 94: 124-128. PMID 8045558 DOI: 10.1007/Bf00202856  0.362
1994 Shinotoh H, Calne DB, Snow B, Hayward M, Kremer B, Theilmann J, Hayden MR. Normal CAG repeat length in the Huntington's disease gene in senile chorea. Neurology. 44: 2183-4. PMID 7969980 DOI: 10.1212/Wnl.44.11.2183  0.382
1994 Nasir J, Lin B, Bucan M, Koizumi T, Nadeau JH, Hayden MR. The murine homologues of the Huntington disease gene (Hdh) and the alpha-adducin gene (Add1) map to mouse chromosome 5 within a region of conserved synteny with human chromosome 4p16.3. Genomics. 22: 198-201. PMID 7959767 DOI: 10.1006/Geno.1994.1361  0.317
1994 Goldberg YP, Telenius H, Hayden MR. The molecular genetics of Huntington's disease Current Opinion in Neurology. 7: 325-332. PMID 7952241  0.32
1994 Lin B, Rommens JM, Graham RK, Kalchman M, MacDonald H, Nasir J, Delaney A, Goldberg YP, Hayden MR. Differential 3' polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Human Molecular Genetics. 2: 1541-5. PMID 7903579 DOI: 10.1093/Hmg/2.10.1541  0.655
1994 Squitieri F, Andrew SE, Goldberg YP, Kremer B, Spence N, Zelsler J, Nichol K, Theilmann J, Greenberg J, Goto J, Kanazawa I, Vesa J, Peltonen L, Almqvist E, Anvret M, ... ... Hayden MR, et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence Human Molecular Genetics. 3: 2103-2114. PMID 7881406 DOI: 10.1093/Hmg/3.12.2103  0.347
1994 Weber B, Riess O, Wolff G, Andrew S, Collins C, Graham R, Theilmann J, Hayden MR. Delineation of a 50 kilobase DNA segment containing the recombination site in a sporadic case of Huntington's disease. Nature Genetics. 2: 216-22. PMID 1345172 DOI: 10.1038/Ng1192-216  0.673
1994 Lin B, Nasir J, MacDonald H, Hutchinson G, Graham R, Rommens J, Hayden M. Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat Human Molecular Genetics. 3: 530-530. DOI: 10.1093/Hmg/3.3.530-A  0.688
1994 Appelman E, Bijvoet S, Wiebusch H, Ma Y, Reymer P, Bruin T, Hayden M, Kastelein J. A de novo mutation in the lipoprotein lipase (LPL) gene causing LPL deficiency Atherosclerosis. 109: 63. DOI: 10.1016/0021-9150(94)93267-0  0.309
1994 Ginzinger D, Krapp A, Zhang H, Gagne S, Beisiegel U, Hayden M. Molecular characterization of a colony of cats with lipoprotein lipase deficiency (LPL) reveals a mutation that impairs catalytic activity and interaction with the LDL receptor-related protein (LRP) Atherosclerosis. 109: 10. DOI: 10.1016/0021-9150(94)93048-1  0.3
1994 Clark CM, Kremer B, Hayden MR. Regional cerebral glucose metabolism in Huntington's disease: A statistical investigation Human Brain Mapping. 2: 95-102. DOI: 10.1002/Hbm.460020109  0.322
1993 Ma Y, Liu MS, Ginzinger D, Frohlich J, Brunzell JD, Hayden MR. Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene. The Journal of Clinical Investigation. 91: 1953-8. PMID 8486765 DOI: 10.1172/Jci116414  0.327
1993 Funke H, von Eckardstein A, Pritchard PH, Hornby AE, Wiebusch H, Motti C, Hayden MR, Dachet C, Jacotot B, Gerdes U. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. The Journal of Clinical Investigation. 91: 677-83. PMID 8432868 DOI: 10.1172/Jci116248  0.333
1993 Weber B, Riess O, Daneshvar H, Graham R, Hayden MR. (CA)n-dinucleotide repeat at the PDEB locus in 4p16.3. Human Molecular Genetics. 2: 827. PMID 8394765 DOI: 10.1093/Hmg/2.6.827  0.602
1993 Hutchinson GB, Andrew SE, McDonald H, Goldberg YP, Graham R, Rommens JM, Hayden MR. An Alu element retroposition in two families with Huntington disease defines a new active Alu subfamily. Nucleic Acids Research. 21: 3379-83. PMID 8393987 DOI: 10.1093/Nar/21.15.3379  0.635
1993 Hayden MR. On planting alfalfa and growing orchids: The cloning of the gene causing Huntington disease Clinical Genetics. 43: 217-222. PMID 8375101 DOI: 10.1111/J.1399-0004.1993.Tb03806.X  0.318
1993 Andrew S, Theilmann J, Almqvist E, Norremolle A, Lucotte G, Anvret M, Sorensen SA, Turpin JC, Hayden MR. DNA analysis of distinct populations suggests multiple origins for the mutation causing Huntington disease. Clinical Genetics. 43: 286-94. PMID 8370147 DOI: 10.1111/J.1399-0004.1993.Tb03820.X  0.323
1993 Ma Y, Liu MS, Zhang H, Forsythe IJ, Brunzell JD, Hayden MR. A 4 basepair deletion in exon 4 of the human lipoprotein lipase gene results in type I hyperlipoproteinemia. Human Molecular Genetics. 2: 1049-50. PMID 8364543 DOI: 10.1093/Hmg/2.7.1049  0.302
1993 Hayden MR, Kastelein JJ, Funke H, Brunzell JD, Ma Y. Phenotypic variation of mutations in the human lipoprotein-lipase gene. Biochemical Society Transactions. 21: 506-9. PMID 8359520 DOI: 10.1042/Bst0210506  0.334
1993 Goldberg YP, Andrew SE, Clarke LA, Hayden MR. A PCR method for accurate assessment of trinucleotide repeat expansion in huntington disease Human Molecular Genetics. 2: 635-636. PMID 8353482 DOI: 10.1093/Hmg/2.6.635  0.321
1993 Telenius H, Kremer HPH, Thellmann J, Andrew SE, Almqvist E, Anvret M, Greenberg C, Greenberg J, Lucotte G, Squltierl F, Starr A, Goldberg YP, Hayden MR. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent Human Molecular Genetics. 2: 1535-1540. PMID 8268906 DOI: 10.1093/Hmg/2.10.1535  0.318
1993 Wood S, Schertzer M, Hayden M, Ma Y. Support for founder effect for two lipoprotein lipase (LPL) gene mutations in French Canadians by analysis of GT microsatellites flanking the LPL gene. Human Genetics. 91: 312-6. PMID 8099055 DOI: 10.1007/Bf00217348  0.316
1993 Tooyama I, Kremer HP, Hayden MR, Kimura H, McGeer EG, McGeer PL. Acidic and basic fibroblast growth factor-like immunoreactivity in the striatum and midbrain in Huntington's disease. Brain Research. 610: 1-7. PMID 7686078 DOI: 10.1016/0006-8993(93)91209-B  0.342
1993 Riess O, Noerremoelle A, Collins C, Mah D, Weber B, Hayden MR. Exclusion of DNA changes in the beta-subunit of the c-GMP phosphodiesterase gene as the cause for Huntington's disease. Nature Genetics. 1: 104-8. PMID 1338767 DOI: 10.1038/Ng0592-104  0.397
1993 Riess O, Weber B, Noeremolle A, Shaikh RA, Hayden MR, Musarella MA. Linkage studies and mutation analysis of the PDEB gene in 23 families with Leber congenital amaurosis. Human Mutation. 1: 478-85. PMID 1338765 DOI: 10.1002/Humu.1380010605  0.328
1992 Weber B, Collins C, Kowbel D, Riess O, Hayden MR. Identification of multiple CpG islands and associated conserved sequences in a candidate region for the Huntington disease gene. Genomics. 11: 1113-24. PMID 1838348 DOI: 10.1016/0888-7543(91)90039-H  0.316
1992 Ma Y, Wilson BI, Bijvoet S, Henderson HE, Cramb E, Roederer G, Murthy MRV, Julien P, Bakker HD, Kastelein JJP, Brunzell JD, Hayden MR. A missense mutation (Asp250----Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. Genomics. 13: 649-653. PMID 1639392 DOI: 10.1016/0888-7543(92)90136-G  0.308
1992 Bergeron J, Normand T, Bharucha A, Ven Murthy MR, Julien P, Gagné C, Dionne C, De Braekeleer M, Brun D, Hayden MR. Prevalence, geographical distribution and genealogical investigations of mutation 188 of lipoprotein lipase gene in the French Canadian population of Québec. Clinical Genetics. 41: 206-10. PMID 1576758 DOI: 10.1111/J.1399-0004.1992.Tb03664.X  0.303
1992 Bruin T, Kastelein JJ, Van Diermen DE, Ma Y, Henderson HE, Stuyt PM, Stalenhoef AF, Sturk A, Brunzell JD, Hayden MR. A missense mutation Pro157 Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity. European Journal of Biochemistry. 208: 267-72. PMID 1521525 DOI: 10.1111/J.1432-1033.1992.Tb17182.X  0.338
1992 Hayden MR, Ma Y. Molecular genetics of human lipoprotein lipase deficiency Molecular and Cellular Biochemistry. 113: 171-176. PMID 1518507 DOI: 10.1007/Bf00231536  0.338
1992 Henderson HE, Hassan F, Berger GMB, Hayden MR. The lipoprotein lipase Gly188→Glu mutation in South Africans of Indian descent: Evidence suggesting common origins and an increased frequency Journal of Medical Genetics. 29: 119-122. PMID 1351946 DOI: 10.1136/Jmg.29.2.119  0.327
1992 Andrew S, Theilmann J, Hedrick A, Mah D, Weber B, Hayden MR. Nonrandom association between Huntington disease and two loci separated by about 3 Mb on 4p16.3. Genomics. 13: 301-11. PMID 1351866 DOI: 10.1016/0888-7543(92)90246-O  0.361
1992 Kremer B, Weber B, Hayden MR. New insights into the clinical features, pathogenesis and molecular genetics of huntington disease Brain Pathology. 2: 321-335. PMID 1341966 DOI: 10.1111/J.1750-3639.1992.Tb00709.X  0.337
1992 Collins C, Hutchinson G, Kowbel D, Riess O, Weber B, Hayden MR. The human beta-subunit of rod photoreceptor cGMP phosphodiesterase: complete retinal cDNA sequence and evidence for expression in brain. Genomics. 13: 698-704. PMID 1322354 DOI: 10.1016/0888-7543(92)90144-H  0.308
1992 Goldberg YP, Lin B-, Andrew SE, Nasir J, Graham R, Glaves ML, Hutchinson G, Theilmann J, Ginzinger DG, Schappert K, Clarke L, Rommens JM, Hayden MR. Cloning and mapping of the α-adducin gene close to D4S95 and assessment of its relationship to Huntington disease Human Molecular Genetics. 1: 669-675. PMID 1284592 DOI: 10.1093/Hmg/1.9.669  0.683
1991 Ma Y, Henderson HE, Ven Murthy MR, Roederer G, Monsalve MV, Clarke LA, Normand T, Julien P, Gagné C, Lambert M, Davignon J, Lupien PJ, Brunzell J, Hayden MR. A mutation in the human lipoprotein lipase gene as the most common cause of familial chylomicronemia in French Canadians New England Journal of Medicine. 324: 1761-1766. PMID 2038366 DOI: 10.1056/Nejm199106203242502  0.34
1991 Clark CM, Ammann W, Martin WR, Ty P, Hayden MR. The FDG/PET methodology for early detection of disease onset: a statistical model. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 11: A96-102. PMID 1825496 DOI: 10.1038/Jcbfm.1991.44  0.32
1991 Henderson HB, Ma Y, Hassan MF, Monsalve MV, Marais AD, Winkler F, Gubernator K, Peterson J, Brunzell JD, Hayden MR. Amino acid substitution (Ile194 → Thr) in exon 5 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in three unrelated probands: Support for a multicentric origin Journal of Clinical Investigation. 87: 2005-2011. PMID 1674945 DOI: 10.1172/Jci115229  0.333
1991 Hayden MR, Yuanhong M, Brunzell J, Henderson HE. Genetic variants affecting human lipoprotein and hepatic lipases Current Opinion in Lipidology. 2: 104-109. DOI: 10.1097/00041433-199104000-00008  0.305
1990 Bloch M, Hayden MR, Schömig-Spingler M. DNA testing for Huntington disease results in a modification of risk and not diagnosis of disease European Journal of Pediatrics. 149: 513. PMID 2140774 DOI: 10.1007/Bf01959407  0.306
1990 Kastelein JJP, Haines JL, Hayden MR. The gene causing familial hypoalphalipoproteinemia is not caused by a defect in the apo AI-CIII-AIV gene cluster in a Spanish family Human Genetics. 84: 396-400. PMID 1969839 DOI: 10.1007/Bf00195807  0.325
1989 Langlois S, Deeb S, Brunzell JD, Kastelein JJ, Hayden MR. A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. Proceedings of the National Academy of Sciences of the United States of America. 86: 948-52. PMID 2536938 DOI: 10.1073/Pnas.86.3.948  0.35
1989 Fahy M, Robbins C, Bloch M, Turnell RW, Hayden MR. Different options for prenatal testing for Huntington's disease using DNA probes Journal of Medical Genetics. 26: 353-357. PMID 2525622 DOI: 10.1136/Jmg.26.6.353  0.313
1988 Wasmuth JJ, Hewitt J, Smith B, Allard D, Haines JL, Skarecky D, Partlow E, Hayden MR. A highly polymorphic locus very tightly linked to the Huntington's disease gene Nature. 332: 734-736. PMID 3386718 DOI: 10.1038/332734A0  0.37
1988 Makrides SC, Ruiz-Opazo N, Hayden M, Nussbaum AL, Breslow JL, Zannis VI. Sequence and expression of Tangier apoA-I gene European Journal of Biochemistry. 173: 465-471. PMID 3129297 DOI: 10.1111/J.1432-1033.1988.Tb14022.X  0.325
1988 Jason GW, Pajurkova EM, Suchowersky O, Hewitt J, Hilbert C, Reed J, Hayden MR. Presymptomatic neuropsychological impairment in Huntington's disease. Archives of Neurology. 45: 769-73. PMID 2968784 DOI: 10.1001/Archneur.1988.00520310079021  0.341
1987 Bloch M, Hayden MR. Preclinical testing in Huntington disease American Journal of Medical Genetics - Seminars in Medical Genetics. 27: 733-734. PMID 2957915 DOI: 10.1002/Ajmg.1320270333  0.321
1986 Suchowersky O, Hayden MR, Martin WR, Stoessl AJ, Hildebrand AM, Pate BD. Cerebral metabolism of glucose in benign hereditary chorea. Movement Disorders : Official Journal of the Movement Disorder Society. 1: 33-44. PMID 2973557 DOI: 10.1002/Mds.870010105  0.309
1986 Clark CM, Hayden MR, Stoessl AJ, Martin WRW. Regression model for predicting dissociations of regional cerebral glucose metabolism in individuals at risk for Huntington's disease Journal of Cerebral Blood Flow and Metabolism. 6: 756-762. PMID 2947906 DOI: 10.1038/Jcbfm.1986.132  0.301
1985 Gusella JF, Tanzi RE, Bader PI, Phelan MC, Stevenson R, Hayden MR, Hofman KJ, Faryniarz AG, Gibbons K. Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. Nature. 318: 75-8. PMID 2997623 DOI: 10.1038/318075A0  0.357
Show low-probability matches.